Meet GenDx at ASHI 2023

We are happy to announce that GenDx is supporting ASHI 2023 with a platinum sponsorship! The conference will be held this year from Monday, October 16, to Friday, October 20.
Make sure to join us in our activities!

Teaching Session (on site training)

Monday, October 16, 2023, 9:00 AM – 4:30 PM PDT | San Antonio Marriott Rivercenter

This year’s training will have 2 sesions. The morning session will focus on advanced data analysis and case studies using our NGSengine software. The afternoon session will focus on new sequencing technologies for HLA typing, including our new NGS-Turbo workflow and data analysis. NGS-Turbo is a High Resolution typing assay using Oxford Nanopore sequencing.

More information and registration here

GenDx User Group Meeting

Tuesday, October 17, 12:15 pm – 02:05 pm | San Antonio Marriott Rivercenter

User’s Perspective on New Technologies: Improving HLA Typing workflows using Nanopore & Chimerism Monitoring with NGS

12:15pm Welcome & Introduction, Maarten Penning PhD, CTO & General Manager at GenDx
12:30pm User’s Perspective: Real Time PCR & Nanopore Sequencing Comparison, Alison J. Gareau, PhD, D(ABHI)
1:00pm User’s Perspective: Post Transplant Monitoring with STR & NGS , Valia Bravo-Egana, PhD, F(ACHI), MBA
1:30pm GenDx New Developments, Hanneke Merkens PhD, CMO at GenDx
2:00pm Wrap-up Final Questions, Maarten Penning PhD, General Manager at GenDx

 

Tulip Run

Wednesday, October 18, 6:30 am – 8:00 am | San Antonio Convention Center

Join us on this morning run, sponsored by GenDx, and contribute to a common goal: enhancing the outcome of transplantation. All runners and walkers are welcome. Don’t forget to add the run to your meeting registration!

More information on the ASHI Tulip Run can be found here. Find photos from previous Tulip Run events here

Posters 

Our poster will be available online on the ASHI platform and in person during the meeting.

    • HLA loss detection by NGS using a multiplex of 16 markers within the MHC region

Job Geerligs, Lisa Rond, Fereshte Dadkhodaie, Loes van de Pasch, Maarten Penning, Sake van Wageningen

 

For more information and registration at ASHI, visit https://www.ashi-hla.org/

Looking forward to seeing you there!

NGSengine® has been updated

NGSengine 3.1 now available!

NGSengine®, our software for NGS-based HLA analysis, was developed in 2012 and has since undergone major developments. Customer feedback has been the driving force behind our continuous commitment to enhancing our software. Throughout the years, we have consistently elevated the standards for optimal result visualization and dedicated efforts to refining our algorithms, ensuring that we deliver reliable typing results.

We are proud to announce the changes we have made and we trust that they will further enhance your experience with NGSengine! Among the key improvements in NGSengine 3.1. you can find:

  • New phasing algorithm
  • Improved insertion detection and reporting
  • Improved ignore region management
  • New options to display ambiguities in the genotype ranking view
  • Extended analysis region for DPB1
  • Improved user experience

Update now
Make sure to update your software to the latest version. For a complete overview of the improvements, other changes and bugfixes, please check the release certificate. You can also find the latest instruction for use documents for NGSengine here.

Download NGSengine 3.1

Download release certificate – NGSengine 3.1

Download release certificate – NGSignition 3.1

 

Meet GenDx at EFI 2024

We are happy to announce that GenDx will be present at EFI 2024 in Geneva with a platinum sponsorship! The conference will be held this year from Monday, May 20, to Thursday, May 23.
Make sure to join us in our activities!

Teaching Session (on-site training)

Monday, May 20, 9:00 AM – 4:00 PM | Palexpo – Geneva

This year, we will have two sessions. The morning session will focus on high sensitivity in Chimerism monitoring and on the available solutions offered by GenDx. During the afternoon session, we will deep dive into our new sequencing technologies for HLA typing: NGS-Turbo; we will explain how the workflow works and demonstrate the sequencing and data analysis live during the session. Milena Vraná from IHBT Praha will give insights into her experience an NGS-Turbo user.

More information and registration here

Tulip Run

Wednesday, May 22, 6:40 AM – 8:00 AM | Sarasin Park

Join us on this morning run, sponsored by GenDx, and contribute to a common goal: enhancing the transplantation outcome. All runners and walkers are welcome. Don’t forget to add the run to your meeting registration!

The meeting point will be at the main entrance of the Palexpo Geneva at 6:15 AM.

More information on the EFI Tulip Run can be found here. Find photos from previous Tulip Run events here

GenDx Symposium

Wednesday, May 22, 1:10 PM – 1:50 PM | Hall A

Join our Industry Symposium “Timeless Expertise: innovations in HLA Typing” and get updates on our latest developments.

Speakers: Timo Olieslagers from Maastricht University Medical Center

 

For more information and registration at EFI, visit https://efi-conference.org/

Looking forward to seeing you there!

Holiday Closure 2023

GenDx will be closed from December 25 to January 2, 2024. If you want to make an order before the end of the year, make sure to place it before December 19 (within Europe) or before December 15 (Rest of World) to get your order processed this year (subject to stock availability). Orders received after this date will be shipped in the week of January 2 (within Europe) or in the week of January 9 (Rest of World). For urgent matters that cannot wait, our support team will remain reachable during the closure via support2023@gendx.com

GenDx Announces a Collaboration Agreement with OSE Immunotherapeutics

PRESS RELEASE

Utrecht, 21 November 2023

During the opening of their new offices GenDx Announces a Collaboration Agreement with OSE Immunotherapeutics for the Development of the NGSgo® HLA-A typing kit and NGSengine® software as a Companion Diagnostic for an Epitope-Based Cancer Vaccine.

GenDx, a Eurobio Scientific Company, today announced that the Company has entered into a collaboration with OSE Immunotherapeutics (a French biotech company dedicated to developing first-in-class assets in immuno-oncology) to develop and validate a companion diagnostic (CDx) test for high resolution typing of HLA-A*02 based on their IVDR registered NGSgo® kit and NGSengine® software. This test will support the confirmatory pivotal Phase 3 clinical trial of Tedopi® cancer vaccine in preparation in Non-Small Cell Lung Cancer (NSCLC) second line treatment.
Under the Master Collaboration Agreement, GenDx will develop and validate a companion diagnostic test for a predictive immunological biomarker to identify patients with HLA-A*02 genotype who are biological responders to Tedopi® epitopes. The CDx test, based Next-Generation Sequencing (NGS) technology, will support the enrolment of eligible NSCLC patient in the upcoming registration pivotal Phase 3 of Tedopi®. The objective of this study will be to confirm the efficacy and safety of Tedopi® in second line treatment post-immune checkpoint inhibitor (ICI) failure in HLA-A*02 positive NSCLC patients to support Tedopi®’s registration in both United States and Europe.
This first announcement of GenDx’ step towards the companion diagnostic market falls together with the opening of their new offices located at the Utrecht Science Park. As the new location provides an expansion of the offices, production, and R&D facilities, GenDx can now can keep on supporting the growing demand of customers globally for innovative products for transplant diagnostics. The new office reflects GenDx’ commitment to foster innovation and collaboration within the transplant community. It will also serve as a center for hosting training courses and it houses a new studio to provide online education to the HLA-typing community.

Maarten Penning, General Manager of GenDx, says:
“In this project, our regulatory expertise, illustrated by being one of the first IVDR compliant companies, and our extensive knowledge of developing software and reagents for accurate high resolution HLA typing using NGS, come together in the development of a companion diagnostic assay for HLA-A*02. We are very happy to enter in this strategic collaboration with OSE, as we aim to contribute to improve the quality of life and survival of patients.”

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments:
“Through this strategic collaboration, we are very pleased to be working with GenDx, the leading high-resolution HLA typing company. This companion diagnostic test will be useful for selecting HLA-A*02 eligible cancer patients and thus accelerating the clinical development and regulatory registration of Tedopi® as a precision medicine innovative treatment”

About HLA
The Human Leukocyte Antigen (HLA) system comprises a diverse family of genes and allelic variants crucial for the human immune system. Precise HLA matching between patients and donors is essential in transplantation, as even slight differences in HLA alleles can significantly impact transplant outcomes. HLA typing enables the identification of specific nucleotide sequences, making it an indispensable tool for transplantation purposes.

About GenDx, a Eurobio Scientific Company
Genome Diagnostics B.V., trading as GenDx, is a Dutch company specializing in molecular diagnostics. It focuses on the development, production, and sale of innovative assays and analysis software for transplantation and companion diagnostics. GenDx offers a range of HLA sequencing-based typing strategies, reagents, software, and custom laboratory services. GenDx Education also provides dedicated training courses worldwide for professionals in tissue typing, research laboratories, blood banks, and donor registries. In
October 2022, Eurobio Scientific acquired all shares of GenDx. For more information, visit www.GenDx.com.

About Eurobio Scientific
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in France in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK,
Sissach Switzerland, Bünde Germany, Antwerp Belgium, Milan in Italy and Utrecht in the Netherlands. Eurobio Scientific’s reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the “Pépites et Territoires” by AXA & NextStage AM investment program, managed by NextStage AM. For more information, please visit : www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME
150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation. The Company’s current portfolio is well-balanced first-in-class clinical pipeline including Tedopi®, OSE-279 (anti-PD1), OSE-127 (lusvertikimab), FR-104/VEL-101 (anti-CD28 monoclonal antibody) developed in partnership with Veloxis Pharmaceuticals, Inc., BI 765063 and BI 770371 (anti-SIRPα monoclonal antibody) developed in partnership with Boehringer Ingelheim. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies: BiCKI® platform focused on immunooncology (IO) and the Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com

GenDx
Yalelaan 48
3584 CM Utrecht
The Netherlands
Office: +31 30 252 3799
E-mail: info@gendx.com

Contact GenDx: Hanneke Merkens PhD, Chief Marketing Officer GenDx , Email: h.merkens@gendx.com , Phone: +31 612655845
NGSgo® , NGSengine® and GenDx are registered trademarks of Genome Diagnostics B.V.

Contact OSE Immunotherapeutics: Nicolas Poirier, Chief Executive Officer, nicolas.poirier@ose-immuno.com

 

Introducing NGSengine-Turbo 1.0.0

GenDx proudly presents NGSengine-Turbo version 1.0.0, the NGS-Based HLA typing software designed to streamline the analysis of data generated with our NGS-Turbo assays. NGSengine-Turbo introduces a range of powerful features that will greatly improve the way you approach fast HLA typing.

Key Features of NGSengine-Turbo:

  1. Regular Updates Included: With at least two updates per year, NGSengine-Turbo ensures that you’re equipped with the latest databases. This means you can focus on your research, confident that your software is always up-to-date.
  2. Intuitive Interface: Simplicity and efficiency are paramount in your work. NGSengine-Turbo’s intuitive interface ensures that you can navigate through the software with ease.
  3. Built on the Renowned NGSengine Software: NGSengine-Turbo is built upon the solid foundation of the renowned NGSengine software. This robust platform has been meticulously fine-tuned to optimize data analysis for ONT data, ensuring the highest level of precision and reliability. Trust in your HLA typing results with NGSengine-Turbo.

A Closer Look:

After the sequencing process, NGSengine-Turbo provides rapid data analysis within minutes. The software’s advanced algorithms, developed based on the tried-and-true NGSengine, guarantee exceptional accuracy and performance, specifically tailored for ONT data.

The reporting process is straightforward and user-centric, delivering precisely the information you need to effectively communicate your typing results.

NGSengine-Turbo is now available as a Research Use Only (RUO).

Interested?

Interested to try out NGSengine-Turbo 1.0.0?

Contact now our Support Team to request a trial licence!

 

GenDx launches NGS-Turbo®

PRESS RELEASE

Utrecht, 17 October 2023

GenDx launches NGS-Turbo®: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices

GenDx, a Eurobio Scientific Company, has announced the launch of their newly developed product, NGS-Turbo, designed for HLA typing using Oxford Nanopore Technologies sequencing devices. NGS-Turbo represents a significant leap forward in the field of HLA typing, offering unparalleled speed and efficiency when time is of the essence.
With the release of this new product, GenDx continues to push the boundaries of innovation in the field of HLA typing, and NGS-Turbo demonstrates their commitment to providing cutting-edge solutions for the transplantation community.
NGS-Turbo is characterized by its exceptional turnaround time, providing high-resolution HLA typing results in as little as three hours, from blood sample to the final result. The innovative product is composed of two essential workflow components: NGS-TurboAmp and NGS-TurboPrep.
NGS-TurboAmp facilitates rapid amplification, completing the process in a mere 90 minutes, targeting 11 HLA loci using a whole-gene approach.
NGS-TurboPrep offers a library preparation designed specifically for Oxford Nanopore sequencing devices. In just 30 minutes, users can perform library preparation in a single well with little effort, thanks to pre-filled color-coded reagents. The preparation process eliminates the need for fragmentation, can be conducted at room temperature, and offers the flexibility to pause if necessary.
The sequencing step, performed on an Oxford Nanopore device, takes as little as 20 minutes to generate high-quality data, ensuring precise and accurate typing results.

Maarten Penning, PhD, General Manager of GenDx, expressed his excitement about the product’s launch, stating, “We are continuously evolving our HLA typing product lines to meet the dynamic demands of the field. Our collaboration with Oxford Nanopore has led to the development of an assay that not only seamlessly integrates with their platform but also excels in speed and user-friendliness. The overwhelmingly positive feedback received during the early access program speaks volumes about the product’s potential impact. NGS-Turbo will be a transformative solution for laboratories seeking high-resolution HLA typing with rapid turnaround times.”
For more information about NGS-Turbo and GenDx’s comprehensive range of HLA typing solutions, please visit www.gendx.com.

About HLA

The Human Leukocyte Antigen (HLA) system comprises a diverse family of genes and allelic variants crucial for the human immune system. Precise HLA matching between patients and donors is essential in transplantation, as even slight differences in HLA alleles can significantly impact transplant outcomes. HLA typing enables the identification of specific nucleotide sequences, making it an indispensable tool for transplantation purposes.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

About GenDx, a Eurobio Scientific Company

Genome Diagnostics B.V., trading as GenDx, is a Dutch company specializing in molecular diagnostics. It focuses on the development, production, and sale of innovative assays and analysis software for transplantation and companion diagnostics. GenDx offers a range of HLA sequencing-based typing strategies, reagents, software, and custom laboratory services. GenDx Education also provides dedicated training courses worldwide for professionals in tissue typing, research laboratories, blood banks, and donor registries. In October 2022, Eurobio Scientific acquired all shares of GenDx. For more information, visit www.GenDx.com.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 170 employees and three production units based in France, in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands. Eurobio Scientific’s reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the “Pépites et Territoires” by AXA & NextStage AM investment program, managed by NextStage AM. For more information, please visit : www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

GenDx Yalelaan 48, 3584 CM Utrecht, The Netherlands, Office: +31 30 252 3799, E-mail: info@gendx.com

Contact GenDx: Hanneke Merkens PhD, Director Marketing and Communication Email: m.merkens@gendx.com, Phone: +31 6 12 65 5845

Download the full press release here

Read more about NGS-Turbo here

 

 

Run with us at the GenDx Tulip Run during BSHI 2023

Are you also joining BSHI 2023, in Birmingham? Get ready for another exciting Tulip Run with GenDx!

Calling all immunology enthusiasts attending BSHI 2023! If you’re preparing for the conference, we’ve got exciting news! GenDx and our distributor, Alpha Biotech will be right there, and we’re thrilled to announce another Tulip Run!

Event Details:

  • Date: Wednesday, September 13th
  • Time: 07:00 AM
  • Running Route: A scenic 5km loop around Edgbaston Reservoir.
  • Meeting Time: 6:40 AM in front of the Park Regis Hotel, Birmingham.

About the Tulip Run: At GenDx, we believe that sharing knowledge and ideas is the cornerstone of progress in the transplantation field. That’s why we’ve introduced the Tulip Run – an event that brings together science, fresh air, and the thrill of a run or walk. Originally launched at ASHI and EFI meetings, the Tulip Run has become a global phenomenon, encouraging open discussions, innovative thinking, and lasting connections among like-minded researchers.

How to Participate: To take part in the Tulip Run, please complete a waiver form and hand into the Alpha Biotech stand. There will be copies available during the conference. Free T-shirts for all runners (to be collected from the Alpha Biotech stand on day 1 of conference).

We’re excited to see you at the starting line!

 

Find photos from previous events here

 

Run with us at the GenDx Tulip Run during ASHI 2023

Wednesday, October 18, 2023
6:30 am – 7:30 am
San Antonio Convention Center

Are you also coming to ASHI 2023 in San Antonio? Walk or run the Tulip Run, sponsored by GenDx, and join us on the common goal: enhancing the outcome of transplantation.

The run is a great opportunity to have an energetic start of the day, while contributing to a fantastic cause. Whether you are a seasoned runner or just starting out, this event is open to everyone who wants to participate.

Participants can choose to either run or walk a 5k route through the streets of San Antonio! We will begin and end at the Convention Center. We encourage everyone to challenge themselves and push their limits.

Fee is $25 per person. Proceeds from this event will benefit a local OPO in San Antonio, TX.

Don’t forget to add the run to your meeting registration and pack your running shoes!

Read more about Tulip Run and find photos from previous events here

 

IVDR Compliance: Our journey

At GenDx the quality and safety of our products and services has always been a key priority. This includes having the proper certificates in place for both the quality management system as well as for the GenDx products.

GenDx’ journey towards IVDR compliance

When the first news came in 2017 that the IVDR (In Vitro Diagnostic Regulation) would be implemented May 2022 there was no hesitation to become compliant and continue to meet the highest standards.  Especially since the main aim of IVDR is to better safeguard the quality and safety of products for the benefit of patients; which lies close to our hearts.

Preparation and Implementation: Overcoming challenges

Most of the GenDx products were already CE-marked under the IVDD (In Vitro Diagnostic Directive) when IVDR was introduced which is a good basis to start from. Upon joining GenDx in 2019, the quality assurance and regulatory affairs colleagues had already prepared for IVDR readiness with gap analysis between IVDD and IVDR and preliminary transition plans.

In the three years that followed that plan was extended and all teams were involved to discuss and align on how to implement the legislation to the GenDx processes in a way that would be compliant but also practical for the employees. Meanwhile, the work on the technical documentation for first product’s in line to become IVDR compliant started as well as the updating of standard operating procedures and protocols. Management’s commitment was crucial in enabling these projects with sufficient resources.

It turned out that the major challenges lay in understanding IVDR requirements, than get it implemented with the proper documentation and last but not least to get this in line with the evaluation criteria of the Notified Body. Fortunately, GenDx already had a good relationship with their notified body TUV SUD, and since GenDx was amongst the first companies to apply for IVDR there was enough time and opportunity to align both content as well as timelines.

Achieving milestones and future plans

Since may 2022 GenDx holds an IVDR certificate for the entire NGSgo reagent product portfolio for HLA typing. In addition also NGSengine (HLA typing analysis software) is CE marked under the IVDR as a stand alone device. The latter is an accomplishment that GenDx is particularly proud of since it was one of the first software devices that obtained this status despite the fact that software registration under IVDR turned out to be very challenging from both a procedural as well as a documentation perspective.

In the coming years also the GenDx chimerism product portfolio will be transitioned to be IVDR compliant and all new products will be designed to be compliant from the start. In addition obtaining the CE-mark under IVDR as one of the first companies in our field also enables GenDx to team up with pharmaceutical partners to collaborate in the field of CDX (companion diagnostics) with the aim to help additional patients in different medical fields.

by Erica Kremer PhD, Director Compliance

Find our certificates: https://www.gendx.com/support/certificates/

Unveiling the variability of MR1 genes: Insights from Sake Van Wageningen’s research

Discover the pioneering research conducted by our colleague, Sake Van Wageningen, Senior Scientist in Molecular Diagnostics at GenDx. His recent publication explores the intriguing variability of MR1 genes and its implications for understanding genetic diversity.

As the author explains:

Sake van Wageningen, PhD

‘HLA genes are clustered on chromosome 6. However, a gene with a very similar structure to the HLA class I genes is found on chromosome 1. This gene is called MR1. The structure of MR1 is that of a typical MHC class I gene, with exon 1 coding for a leader peptide and exons 2–4 coding for extracellular domains, including α1- and α2-domains that form the antigen-binding cleft. Unlike classical HLA class I genes, MR1 is assumed to have limited polymorphic positions. We developed a MR1 specific PCR assay and sequenced 56 DNA samples from cells with a diverse set of HLA genotypes. In this relatively small panel we found six allele groups encoding for different MR1 proteins. The data presented in the article is consistent with marked variation in MR1.’

 

To access the full article, click here.

 

Tips & tricks to optimize your NGSgo® Workflow

In our website the nine protocol steps of the NGSgo Workflow can be found here. These videos visualize how to execute the workflow steps and can be used as an addition to the available Instructions for Use. Please note that these videos are not a replacement for the Instructions for Use.

Our dedicated technicians using the workflow are happy to share some tips & tricks to optimize the results of your workflow.

Tips & tricks to optimize your NGSgo® Workflow

Tip 1: Work in a dedicated DNA workplace
PCR amplification is a sensitive technique, therefore you need to adopt clean working practices to avoid sample contamination. In order to prevent contamination, we advise to separate the DNA from the amplification reagents in the pre-amplification lab. Move to a designated DNA workplace and wear a dedicated DNA lab coat when you are going to dispense your DNA into the plate. Additionally, it is strongly recommended to perform pre-amplification and post-amplification procedures in separate rooms. In this way, the chance of contamination is minimized.

Tip 2: Standardization of DNA input
By standardizing the DNA input volume before amplification, you ensure the consistency of the amplification outcome. For singleplex amplification this makes the amplicon pooling very easy and consistent. For the multiplex amplifications MX6-1 and MX11-3 this will also yield consistent sequencing results with similar read depths per sample.

Tip 3: Use 8-well strips
During the NGS workflow, when using a large sample set (>24), it saves time to first aliquot the ligase and/or HiFi mastermix in an 8-well strip. This way it is faster to distribute the mix in the plate using a multichannel pipet.

Tip 4: Beads at room temperature
At the start of the NGS workflow, don’t forget to take the beads that are needed in the next step (DNA cleanup) out of the refrigerator. The beads work optimally at room temperature.

Tip 5: Use a multichannel with a reagent reservoir
If you want to save time during the first bead cleanup, make use of a reagent reservoir in combination with a multichannel pipet. This works well for pipetting the beads, elution buffer and 80% ethanol. By using the multichannel pipet you can fill eight tips at once which makes pipetting easy and fast. Any remaining beads or elution buffer can be re-used.

Tip 6: Re-use the IndX plate 
The IndX plate consists of 96 unique index combinations. A big advantage of this plate is that unused indices can be used at a later time. You can simply store the plate in the freezer and re-use it. This means you can easily run a small amount of samples and save the leftover indices for later.

Tip 7: Use Qubit quantification in the Illumina workflow
After your library preparation is finished the quantification of your library can be simply done by using the fluorescence based Qubit. Using the Qubit will save a significant amount of time. Simply use the correction factor, 1.9, to calculate the final concentration in nM (nanomolars) and you are ready for sequencing.

Tip 8: Tips for using Qubit
The Qubit is an easy and fast fluorescence based quantification method. It is advised to use gloves when handling the Qubit tubes to prevent a dirty tube from influencing the measurement results. An extra tip is to put a glove over the vortex; in this way the Qubit tubes will not be smudged by the vortex rubber.

Tip 9: Use the flow cell calculation sheet
In order to most efficiently use the sequencer flow cell, GenDx has developed a flow cell calculation sheet. This excel tool will calculate the maximum amount of samples that can be loaded, no matter the loci configuration. The calculation is based on an minimum read depth of 500 reads.

After these 9 valuable tips & tricks, you are probably motivated to move to the lab and perform the NGSgo workflow! Use the Instruction for Use for the correct execution of the NGSgo Workflow and check out the Instructional videos here for a visualization of the steps.

Maarten Penning appointed as General Manager of GenDx

PRESS RELEASE

Utrecht, 29 June 2023

The board of GenDx announces that Maarten Penning, PhD, will assume the helm of the company and is appointed General Manager, as Wietse Mulder PhD will step down as CEO per July, 1st 2023. Per the same date, Maarten Penning PhD will also become executive director of the GenDx Board, joining directors, Denis Fortier and Hervé Duchesne de Lamotte, representing Eurobio Scientific, GenDx’s parent company.

Maarten Penning is trained as a molecular biologist and joined GenDx for more than 13 years. He has executed various roles at the company ranging from project management, business development till his current job as CTO where he oversees the global R&D of Eurobio Scientific group. As deputy CEO, he also chaperoned the GenDx leadership team for several years. Maarten Penning is a trusted and respected person in the field and will provide its expertise to support the successful transition to a new era for GenDx, part of the Eurobio Scientific group.

At the same time, the Board announces that Wietse Mulder will continue to support GenDx as Ambassador. In that role he will support the GenDx Leadership Team (members) and will devote a particular attention to marketing and communication, including GenDx’s corporate social responsibility activities. He will also continue to actively represent GenDx, locally, and at international conferences.

Since January 2004, Wietse Mulder has devoted full attention to the GenDx project. From a draft business plan and establishing the company in 2005, developing new products, till today where GenDx has become a well-respected company in the field of transplant diagnostics and intends to become a major player in the market through its combination with Eurobio. Thus, the company is at a milestone while it’s entering the field of companion diagnostics and cfDNA diagnostics.

Wietse Mulder comments: “Leaving executive office of GenDx is a major step in the pursue of my career as Life Science entrepreneur. I am proud that together with Erik Rozemuller and all GenDx colleagues, we have achieved a lot for the transplantation diagnostics market. I enjoyed having worked for almost 20 years at GenDx in a truly collaborative atmosphere. Following last year’s transaction, I feel that we found with Eurobio Scientific the best home to ensure continuity with our partners and clients, and the entrepreneurial spirit needed to further develop GenDx.

I am proud to see that we have maintained the same spirit since we started. Focused on educating workers in the transplant field, enabling better HLA typing, allowing better matching and together with accurate transplant monitoring, increasing the success of solid organ and stem cell transplantation. As an ambassador, I will continue to support GendX with the same commitment/dedication

Maarten Penning comments: “It is an honor to be the successor of Wietse Mulder, after working together since 2010. It’s impossible to fully express what Wietse Mulder does mean for GenDx and colleagues. I am looking forward to continue to support and educate our partners in the transplant diagnostic field. I am motivated to make GenDx even more successful in the coming years, together with the GenDx Leadership Team and all other fantastic GenDx colleagues. Based on the GenDx experiences, I am confident that together we will also have a meaningful contribution to the success of EuroBio Scientific Group.

About GenDx, a Eurobio Scientific Company

Genome Diagnostics B.V., also known as GenDx, is a Dutch company specialized in molecular diagnostics, focused on development, production and sales of innovative assays and analysis software for transplantation and companion diagnostics. To support GenDx’s USA customers it has an office near O’Hare airport, Chicago, IL. GenDx specializes in (Sanger and NGS) HLA sequencing-based typing strategies and offers both reagents and software. As one of the sequencing pioneering companies in the HLA field, GenDx started offering NGS strategies in 2013, consisting of NGSgo® reagents and the software package NGSengine® for various NGS platforms. Additionally, GenDx offers products for chimerism monitoring by qPCR and – launched recently – by NGS: NGStrack® & TRKengine®. Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations. GenDx Education organizes dedicated HLA sequence-based typing and chimerism monitoring training courses worldwide on a regular basis for anyone working in tissue typing or research laboratories, blood banks, and donor registries. GenDx is based in the Alexander Numan building at the Utrecht Science Park, the Netherlands and was founded in 2005 by Erik Rozemuller PhD, Wietse Mulder PhD. In October 2022, Eurobio Scientific acquired all shares of GenDx. For further information about GenDx visit www.GenDx.com.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 180 employees and three production units based in France, in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands. Eurobio Scientific’s reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the “Pépites et Territoires” by AXA & NextStage AM investment program, managed by NextStage AM. For more information, please visit : www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

GenDx Yalelaan 48, 3584 CM Utrecht, The Netherlands, Office: +31 30 252 3799, E-mail: info@gendx.com

Contact GenDx: Hanneke Merkens PhD, Director Marketing and Communication Email: m.merkens@gendx.com, Phone: +31 6 12 65 5845

Download the full press release here

 

 

Torino University licensed cfDNA assay to monitor organ rejection in lung transplants to GenDx, a Dutch transplant diagnostics company

PRESS RELEASE

Utrecht, May 25, 2023

GenDx has obtained a worldwide license from Università degli Studi di Torino (UNITO) for their method to detect donor specific cell free DNA (cfDNA) in patients that have undergone a lung transplant.
To monitor graft survival, patients typically need bronchoscopy or lung biopsies that are invasive, require anaesthesia and are risky. Moreover, these methods suffer from interobserver variability and are expensive. Researchers at UNITO developed a method that instead requires only a blood sample to monitor transplant rejection. The method comprises a sensitive digital droplet PCR assessment of the cfDNA donor fraction and is superior to biopsies in terms of costs, turnaround time and level of sensitivity. The assay, although developed for lung transplant patients, opens a door for broader solid organ transplants as it supports a pan-organ strategy.
This UNITO license broadens the licence agreement that was obtained earlier from Medical College Wisconsin for its method to detect cfDNA in paediatric patients that have undergone a heart transplant.

Wietse Mulder PhD, CEO of GenDx, commented: “Combining the knowledge of both UNITO on cfDNA and GenDx on DNA typing by NGS and real-time PCR in a transplant setting, offers an enormous potential to develop products which can predict early the potential rejection of transplanted organs. We are excited to collaborate with UNITO enabling new options for accurate transplant monitoring”

Statement UNITO, said: “We are glad to start this new collaboration with GenDx and excited to see that a research idea from our group can move forward and hopefully become a kit. Our goal now is to go on with the necessary steps to optimize our method to fit it in a box and validate it in larger cohorts of patients, working in close collaboration with a company that is a leader in the field of molecular diagnostics for transplantation.”

About Cell free DNA
Donor derived cfDNA refers to all non-encapsulated DNA fragments that enter the bloodstream; this mostly happens during apoptosis or necrosis. Analysis of cell free DNA (cfDNA) after solid organ transplantation has been shown to accurately identify and characterize allograft injury and correlate with pathologic findings (e.g. organ rejection).

About the UNITO
The University of Torino (UniTo) in north-west Italy is one of the country’s largest and most prestigious universities. Founded in 1404, UniTo provides quality higher education and research opportunities; many UniTo graduates have achieved international renown. Today, the University of Torino offers over 150 undergraduate and graduate degree programs in almost every field of study. A growing number of programs are taught in English, and Italian language tuition is available for incoming students. The University’s 27 departments offer excellent opportunities for Italian and non-Italian academic staff; doctoral school provides more than 30 doctoral programs.

About Eurobio Scientific
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 148 employees and three production units based in France, in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

Download the full press release here

 

 

GenDx 1/4 Utrecht Marathon: A resounding success with over 2000 participants

This May, GenDx proudly sponsored the 1/4 Utrecht Marathon. With over 2000 participants, the event celebrated the spirit of athleticism, perseverance, and community. As part of our sponsorship, we had the quarter marathon officially named after us—the GenDx 1/4 Marathon. The event drew an impressive participation of more than 2000 enthusiastic runners who embraced the challenge and spirit of the race.

Looking ahead: A multi-year sponsorship

GenDx has signed a contract to sponsor the 1/4 marathon in 2023, 2024 and 2025, solidifying their commitment to the event and the running community at large. With this multi-year partnership, GenDx aims to continue supporting the growth of running culture and empowering individuals to lead healthy and active lives.

Some pictures of the event

 

To learn more about the Utrecht Marathon and upcoming events, visit [https://www.utrechtmarathon.com/].

A retrospective comparison study of chimerism monitoring by NGS and qPCR (GenDx Symposium, EFI 2023)

During EFI 2023, in the GenDx Symposium, we presented a comparison study of chimerism monitoring by NGS and qPCR. In the article below, Maaike Rijkers PhD, Project Manager R&D at GenDx, shares the key highlights of this study.

In general practice, prior to hematopoietic stem cell transplantation, the recipient is first treated to remove most of the diseased cells. Then, hematopoietic stem cells originating from a donor are transferred to the recipient. After transplantation, the recipient is monitored over time in order to detect chimerism. An increasing number of recipient cells, also called increasing mixed chimerism (IMC), is important to detect as it may be a sign that the disease has returned (relapse). In addition to that, it could indicate graft rejection, minimal/measurable residual disease (MRD), or graft versus host disease (GVHD).

Chimerism can be measured using different methods. For all methods, pre-samples, obtained from both the recipient and the donor prior to transplantation, are used to determine informative markers. These informative markers are subsequently used to determine the chimerism percentage in samples obtained post transplantation (Figure 1).

Figure 1. Chimerism monitoring consists of two stages: 1) Genotyping, in order to determine informative markers. 2) In follow-up samples the informative markers are used to determine chimerism percentages over time.

The study was performed In collaboration with the Universitätsklinikum in Essen, we compared two different chimerism monitoring methods. Chimerism testing was performed in Essen using the qPCR-based method KMRtype, KMRtrack and KMRengine software.

Samples of 5 donor-recipient pairs, all including pre-samples and 5 to 7 follow up samples, were collected and sent to GenDx. At GenDx, the samples were tested using the NGS-based chimerism assay NGStrack using TRKengine software. In total, 10 pre- and 28 post-samples were blindly (without pre-knowledge on the qPCR results) tested. The results obtained with NGStrack were then reported, and subsequently compared to the KMR results.

With NGStrack, a high number of informative markers was obtained (between 17 and 25, of which 11 to 16 markers were recipient informative). Trends of all follow-up samples nicely overlap with the KMR data (see Figure 2), including samples with low (up to 0.1%) chimerism. A strong correlation of 0.9899 between KMR and NGStrack was observed (Figure 3).

Figure 2. Chimerism percentages obtained with NGStrack (pink) and KMR (black).

Figure 3. Correlation between results obtained with NGStrack and KMR. Different colours indicate different recipients.

The validated sensitivity of NGStrack is at least 0.5%. With this study, this sensitivity was confirmed. Additionally, we show that a sensitivity of 0.1% can be reached with NGStrack and identical trends are obtained when using NGStrack and KMR assays.

 

Maaike Rijkers PhD

Tulip Run EFI 2023

The Tulip Run during the annual EFI meeting in Nantes was a big success! More than 50 participants joined us as we ran 5k through the stunning Parc du CRAPA de l’Ile Beaulieu.

€1400 was raised from registrations and donations and GenDx doubled the amount, offering ultimately €2800 to ADOT, the French federation for the donation of organs and human tissues. We would like to express our deepest appreciation to all the participants who ran alongside us and contributed to this cause. It’s inspiring to see people come together for a common goal and make a difference in the world!

For those who couldn’t make it, we invite you to visit our Tulip Run Gallery on our website to view some of the amazing pictures from the event.

Thank you for your support, and we look forward to seeing you in our future events!

Until next year at the EFI 2023 in Jerusalem!

Expert Insights – Interview with Prof John Trowsdale: Exploring the genetics of KIR

We had the privilege of speaking with Dr. John Trowsdale, Emeritus Professor, specialist in Immunogenetics, in the Department of Pathology, University of Cambridge UK. Professor John Trowsdale is a world-renowned expert in the field of immunology and has made seminal contributions to our understanding of the immune system and its role in human health and disease.

In this interview, Professor Trowsdale is discussing what inspired him to specialize in this field and how he got started, as well as his views on the future of KIR typing for transplantation and potential medical applications. He also talks about other genes that may be important in transplantation and gives advice for researchers interested in this field. Finally, he talks about recent exciting developments in his research on KIR3DL3 and its potential as a target for cancer therapy.


FIND THE TEXT OF THE INTERVIEW BELOW

What inspired you to specialize in the genetics of immune receptors, and how did you get started in this field?

My first degree was in bacteriology and my PhD in bacterial genetics in 1973, when I became interested in mapping genes. After a stimulating postdoc in Paris I went to the Scripps Clinic in La Jolla and there learnt that it may be possible to apply genetics to human cells in tissue culture, at the time that cloning of human genes was just starting. I was thinking of returning to the UK and I asked Walter Bodmer if he would take me on as a postdoctoral fellow, in Oxford. He agreed and he asked me to start by cloning HLA genes. Those were exciting times as the emerging human gene sequences helped enormously to explain the molecular components of the immune system. I have to admit to having no experience with cloning DNA and I had to learn on the job with several false starts. Luckily for me Walter became head of the prestigious Cancer Research Laboraties in London where many talented researchers were on hand. We went on, collaborating with Stephan Beck, to sequence the first complete human MHC complexes and co-discovered antigen processing genes such as TAP in the MHC.

How do you see this field (KIR typing for transplantation) evolving in the future?

The precise rules for KIR/HLA mismatch, in order to lower the rate of relapse in leukaemia, remain to be more fully understood. The benefit of KIR typing for solid organ transplantation is even less advanced. There is much to learn still, such as precisely how peptides associated with HLA influence KIR, the function of KIR on CD8 T cells and their involvement in NK cell memory.

Do you see potential medical applications for KIR typing other than transplantation?

There are already indications that KIR typing may have a medical application in pregnancy as the KIR types of mother and father influence conditions such as pre-eclampsia. Another potential application is in targeted therapies for cancer, harnessing the power of NK cells. Some laboratories are exploring ways in which activating KIR may be exploited to develop a unique form of vaccination. The importance of KIR in infectious diseases is poorly understood at present as the combination of HLA variation KIR complexity makes it difficult to tease out individual effects.

Are there more genes then HLA and KIR that may be important during transplantation of stem cells or organs?

Of course, ABO blood group typing is critical and genes influencing rare blood types are of emerging interest. No other genes appear to vary as much as HLA and KIR but there are many other receptors that may influence transplantation outcome, including non-classical HLA molecules, such as MIC, and their receptors. KIR-related genes such as LILR are also polymorphic and will be of interest in the future.

What advice would you give to other researchers or clinicians interested in genetics of immune receptors, and how can they get involved in this field?

I would start by talking to the local experts in a tissue typing lab. There are excellent international societies that hold annual meetings, such as the European Federation for Immunogenetics (EFI) and American Society for Histocompatibility and Immunogenetics ASHI. Most developed nations have their own societies, including the Briish Society for Histocompatibility and Immunogenetics (BSHI).

Lastly, could you share any recent or upcoming developments in KIR that you find particularly exciting or promising in your research field?

The function of the conserved but polymorphic KIR3DL3 protein has been mysterious as it does not appear to interact with any HLA molecules. Recently it has been shown to be expressed in  gd and CD8 T cells in the lungs and digestive tract rather than NK cells in blood. KIR3DL3 appears to interact with a B7 family ligand, HHLA2, making it a target for cancer therapy as an immune checkpoint.

Join the GenDx satellite symposium at EFI 2023

Are you interested in exploring new worlds in HLA and Chimerism research? Join our upcoming scientific symposium during the EFI conference!

This symposium will take place on Friday, April 28th from 12:10–13:10 in Room 300. We have an exciting lineup of speakers who will discuss cutting-edge research and innovative solutions in HLA and Chimerism.

We are looking forward to seeing you there!

GenDx at EFI 2023 in Nantes

EFI 2023 is almost here! The event takes place in Nantes on 26-29 April and GenDx is a platinum sponsor.

The theme for this year is « Big Data In Immunogenetics At The Crossroad Of Care, Tools, And Research » which highlights new challenges of immunogenetics.

We will be very happy to welcome you and your colleagues to our booth (booth #2) for a software demonstration, any question you may have, or to learn more about our latest products.

Also this time, we have prepared for you several activities! Join our Teaching Session (April 26, 09:00-16:30), attend our Satellite Symposium “Exploring New Worlds for HLA and Chimerism: Dare to Discover Innovative Solutions” (April 28, 12:10-13:10, Room 300) and of course, participate in the famous Tulip Run!

Are you also joining EFI? We look forward to seeing you!

GenDx participant in METHYLOMIC project

GenDx is proud to participate in METHYLOMIC, a study funded by the European Union. The project is aiming to enhance the effectiveness of medication in chronic immune-mediated diseases such as Crohn’s Disease (CD), Rheumatoid Arthritis (RA), and Psoriasis (PsO).

As experts in developing personalized diagnostic assays and software, GenDx partnered with Amsterdam UMC in 2017, in various precursors of the METHYLOMIC project. In this collaboration, we bring together scientific expertise with commercial and regulatory proficiency, facilitating the translation of scientific findings regarding differential methylation profiles in Crohn’s into a reliable, fast, affordable and user-friendly test for clinical diagnostics.

Participation in the METHYLOMIC project allows GenDx to establish all required collaborations that will help create an innovative assay. This allows the consortium to develop a solution that benefits all stakeholders, but most importantly makes life better for patients suffering from Crohn’s disease.

To learn more about the project, visit the recently launched website at https://methylomic.eu.

 

 

New publication about IHIW workshop

I am very happy to have co-authored the paper “Using Cloud Infrastructure to Facilitate Data Collection and Conversion of HLA Diagnostic Data for the 18th International HLA and
Immunogenetics Workshop ” together with Ben Mattern, Matthias Niemann, Eric Spierings et al.

The International HLA and Immunogenetics Workshop (IHIW) is a recurring gathering of researchers, technologists and clinicians where participants contribute to collaborative projects with a variety of goals, and come to consensus on definitions and standards for representing HLA and immunogenic determinants. In the paper we summarize all the technological challenges we overcame in order to be able to host the large scale of data needed for the IHIW website. At the same time the website needed to be simple, functional and user friendly and bring together data from many lab leaders.

Other qualities we focused on were data integrity and privacy as most of the handled data are sensitive scientific data. By the above, the continuation of data and research uploaded are
guaranteed to continue to future workshops.

You can read the paper online at https://pubmed.ncbi.nlm.nih.gov/36754592/

Find more information about the IHIWS workshop here: https://www.gendx.com/2022/05/18th-international-hla-immunogenetics-workshop/

Ioannis Nemparis MSc, Software Developer Bioinformatics at GenDx

Run with us at the GenDx Tulip Run during EFI 2023

Friday, April 28, 06:40 am – 8:00 am | Parc du CRAPA de l’Ile Beaulieu

Are you also coming to EFI 2023 in Nantes? Walk or run the Tulip Run, sponsored by GenDx, and join us on the common goal: enhancing the outcome of transplantation.

The run is a great opportunity to have an energetic start of the day, while contributing to a fantastic cause. Whether you are a seasoned runner or just starting out, this event is open to everyone who wants to participate.

Participants can choose to either run or walk a 5k route in the beautiful park Crapa and we encourage everyone to challenge themselves and push their limits. The event will be professionally timed, so you can track your progress and compete against other runners.

Proceeds from this event will be doubled by GenDx and benefit ADOT, the French federation for the donation of organs and human tissues.

Don’t forget to add the run to your meeting registration and pack your running shoes!

Read more about Tulip Run and find photos from previous events here

 

Meet us at the EWIC 2023

GenDx is attending the 15th East-West Immunogenetics Conference (EWIC), which will be held in the IKEM Congress Centre, Prague, Czech Republic from 15 to 17 March 2023.

Are you also coming? Join our presentation on Thursday, March 16, or just come talk to us!

NGS-Turbo: Rapid, easy, robust high-resolution HLA typing within 4 hours

by  Jan Duiker BASc, Distribution Channel Director at GenDx

Thursday, March 16, 10:40 am – 11:10 am

 

We are looking forward to meeting you in Prague!

 

Download the full scientific programme here

Read more about NGS-Turbo here

 

GenDx Teaching Session before EFI 2023

Are you also joining EFI 2023? Make sure to register to our Teaching Session that takes place on the opening day of the meeting!

This year we offer two sessions, an NGSengine masterclass aimed for more experienced users in the morning and an afternoon session on new sequencing technologies for HLA typing.

Interested? Check here for more info and registration!

There is no fee to attend the course. Attendance to the morning session includes lunch. As limited seats are available, we recommend that you register soon. The registration will close on April 14th. The course is ACHI accredited: 0.45/0.9 continuing education credits (CECs) or 3.0/ 6.0 contact hours

We are looking forward to meeting you on our event!

GenDx partners Azure Biosystems to demonstrate chimerism monitoring compatibility with Azure Cielo 6

GenDx has partnered with Azure Biosystems, a leading provider of innovative bioanalytical solutions for protein and genomic research, to demonstrate compatibility of the Azure Cielo 6 qPCR System with the GenDx KMRtype® and KMRtrack® kits for high-sensitivity chimerism monitoring by qPCR.

Azure’s work with GenDx demonstrates the Azure’s Cielo 6’s compatibility with KMRtype and KMRtrack assays. Cielo 6 is easily integrated into the KMRtype and KMRtrack workflows and delivers reliable results in both genotyping and monitoring. Cielo 6 is also integrated in the analysis software, KMRengine.

Azure and GenDx have worked together to publish an application note describing how to integrate the Cielo 6 into the associated workflows, click here to read it.

KMRtype, KMRtrack and KMRengine are available as RUO and IVD, read more about them here

For more information regarding Cielo, visit www.azurebiosystems.com 

Discover our NGS approach for chimerism monitoring

NGStrack® & TRKengine®

Our NGStrack assay combines the use of NGS with highly sensitive indel markers to monitor chimerism. The latest design of the assay, released as of today, has 34 markers multiplexed in just 2 mixes. This setup allows for a DNA input of only 60 ng per sample. Ultimately, the results are visualized in just a few steps with our user-friendly and intuitive software, TRKengine.

The assay: NGStrack®

High-sensitivity chimerism monitoring
With NGStrack you can reach at least 0.5% sensitivity, which is 2-10 times more sensitive than STR assays. The kit features 34 markers multiplexed in 2 mixes for a fast workflow and excellent quality. After a single typing experiment on a pre-sample, all monitoring samples can be measured without the need to include the pre-sample again. The markers overlap with our qPCR KMR reagents, allowing parallel use of the two techniques. Additionally, NGStrack can be combined with NGSgo HLA samples on the same flow cell.

Benefits

✓ Reliable at all chimerism percentages
✓ 2-10 times more sensitive than STR
✓ Only 60 ng DNA needed per sample
✓ Short workflow, 75 min hands-on
✓ Test the pre-sample only once

The software: TRKengine®

Easy trend analysis
Assay results can easily be imported in our intuitive software, TRKengine. The analysis takes just a few minutes and the use of indels, detection is even possible below the sequencing noise levels. The user-friendly interface provides extensive options for donor/recipient management and allows for effortless trending over time.

Benefits
✓ Fast data analysis <5 min
✓ User-friendly overviews
✓ Trend and report chimerism over time
✓ Extensive database management
✓ Works on a standard PC or laptop

Ready to start chimerism monitoring by NGS?

NGStrack and TRKengine are now available for research use only (RUO). Contact us to ask for a demo or for additional information, we will be happy to answer your questions!

Order now!

Request a demo

Tulip Run ASHI 2022

The Tulip Run during the annual ASHI meeting in Las Vegas was a big success!

Together with more than 100 participants, we did the 5k run through the beautiful Sunset Park. $2925 was raised from registrations and donations and GenDx doubled the amount, offering ultimately $5850 to the Nevada Donor Network.

You can check the pictures of the event by visiting the Tulip Run Gallery on our website.

Until next year at the ASHI 2023 in San Antonio!

 

MDSAP certification for Brazil

We are excited to share that GenDx received the new certification for our MDSAP-compliant quality system by our notified body TÜV SÜD. The scope of the certification entails the design, development, manufacture and distribution of In Vitro Diagnostic Medical Devices including software. Besides the regulatory requirements of Canada, our MDSAP quality system now also covers the Brazilian regulations.

The MDSAP certificate is a prerequisite to register our products as in-vitro diagnostic (IVD) device in Brazil.

 

 

Eurobio Scientific finalizes acquisition of Dutch Transplant Diagnostics firm GenDx

PRESS RELEASE

Per today the Paris, France-based Eurobio Scientific (“Eurobio”) acquires all outstanding shares of GenDx (also known as Genome Diagnostics) as was publicly announced after signing the Share Purchase Agreement on 17 August.

ad tempus vitae

This transaction is the result of an intensive project called ad tempus vitae (“ATV”), meaning ‘to prolong life’. This term carries double meaning. Firstly, it refers to GenDx’s offering of products and services aimed at prolonging the life of transplant patients. Secondly, it refers to prolonging the life of the Company, GenDx, by securing the legacy of the founders , which has been built over the last 18 years. The GenDx ATV project was coordinated by Jason Arnold and his London-based M&A advisory team at William Blair, with legal support from Herke van Hulst, Wouter Kok and team at Osborne & Clarke in Amsterdam. RSM provided vendor financial due diligence services to the Company.

Fostered by the adagium of ‘meaningful entrepreneurship’, Mulder and Rozemuller will establish the ‘GenDx foundation’, funded by proceeds of this transaction, aiming at supporting educational and R&D activities in the field of transplantation.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for

research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 148 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

Eurobio Scientific’s reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the “Pépites et Territoires” by AXA & NextStage AM investment program, managed by NextStage AM.

For more information, please visit : www.eurobio-scientific.com

The company is publicly listed on the Euronext Growth market in Paris

Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

 

About GenDx

Genome Diagnostics B.V., also known as GenDx, is a Dutch company specialized in molecular diagnostics, focused on development, production and sales of innovative assays and analysis software for transplant and companion diagnostics. To support GenDx’s USA customers it has an office near O’Hare airport, Chicago, IL.

GenDx specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. As one of the pioneering companies in the HLA field with Sanger approaches, GenDx started offering NGS strategies in 2013, consisting of NGSgo® reagents and the software package NGSengine® for various NGS platforms. Additionally, GenDx offers products for chimerism monitoring by qPCR and – launched recently – by NGS: NGStrack® & TRKengine®.

Recently a license was obtained from California based company Dovetail Genomics (now part of Cantata Bio) allowing GenDx to explore their hybrid capture approach enabling HLA genotyping and ultimately haplotyping of HLA genes.

Furthermore, GenDx obtained another worldwide license from Medical College Wisconsin (MCW) for their patented method to detect donor specific cell free DNA (cfDNA) in pediatric patients that have undergone a heart transplant. And, last month GenDx has signed a non-exclusive service agreement with Oxford Nanopore Technologies (Oxford Nanopore), to bring its new NGS-Turbo® product to the transplant market for high-resolution HLA typing with a turnaround time of less than four hours, enabling improved matching of solid organs in situations where time is a critical factor.

Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations. GenDx Education organizes dedicated HLA sequence-based typing and chimerism monitoring training courses worldwide on a regular basis. The training courses are applicable for anyone working in tissue typing or research laboratories, blood banks, and donor registries.
GenDx is based at the Utrecht Science Park (USP), the Netherlands, and was founded in 2005 by Erik Rozemuller PhD and Wietse Mulder PhD as a spinoff of UMC Utrecht and helped by a 2002 Biopartner First Stage Grant. In 2019, Ampersand Capital Partners acquired a minority stake in the Company.
Currently, GenDx is located at USP in two opposite buildings: Alexander Numan and Androclus. In Q1-2023, GenDx will expand its footprint in A. Numan building by additionally leasing the top three floors of that building. The activities in Androclus will gradually be migrated to Numan building. Total facilities will encompass more than 3000 m2.
For further information about GenDx visit www.GenDx.com.

Download the full press release here

Download press release of Eurobio Scientific here

 

 

YOU can give a chance to live!

UPDATE

The results of this year’s stem cell donor recruitment day are in! 129 people registered using our event code, meaning that GenDx donates €4.515, to Matchis.

A big thank you to everyone who contributed to this year’s edition. Whether you helped with promoting the event, helped spreading awareness on the topic, or volunteered during the event. Together, we reached our goal, which was to motivate as many young, healthy people as possible to join the stem cell donor registry.

We look forward to continuing our collaboration with the Matchis foundation next year. In 2023, the event will again take place in the week of the world marrow donor day.


In the week preceding the World Marrow Donor Day, GenDx is organizing an annual Stem Cell Donor Recruitment Day. This initiative is established in cooperation with Matchis, the Dutch center for stem cell donors, and in line with GenDx’s mission to improve the quality of life and survival of transplant patients. Our main aim is to motivate as many young, fit people to register as a potential stem cell donor.

This year, the event takes place on Thursday 15 September 2022 at various locations, mainly at Utrecht Science Park, but also in Leiden (LUMC).

Do you want to make a difference for a patient who needs a stem cell transplant to get a chance to live?  Join the stem cell donor registry! 

If you register using our event code ‘GENDX22’, GenDx will support the Matchis Foundation financially by covering the costs they make for processing your registration, i.e. 35 euros. The code is valid from 12 – 23 September, surrounding our annual Stem Cell Donor Recruitment Day.

Read more about it here: Stem Cell Donation

September 13 we will have special webinars to raise awareness on the topic. Click here to register

Meet GenDx at ASHI 2022

We are happy to announce that GenDx is supporting ASHI 2022 with a platinum sponsorship! The conference will be held this year from Monday, October 24 to Friday, October 28.
Make sure to join us in our activities!

Teaching Session

Monday, October 24, 2022, 10:00 AM – 5:00 PM PDT | Las Vegas

Join our training and become an expert in HLA typing. This course will focus on HLA typing by NGS and is aimed for both beginners and advanced users.

More information and registration here

Tulip Run

Wednesday, October 26, 6:30 am – 7:30 am | Sunset Park, Las Vegas, NV

Walk or run to this event, sponsored by GenDx, and join us on the common goal: enhancing the outcome of transplantation. Proceeds from this event will benefit a local OPO in Las Vegas, Nevada. All runners and walkers are welcome. Don’t forget to add the run to your meeting registration!

More info about the event here.

Find photos from previous Tulip Run events here

User Group Meeting: Why Gamble on your Rapid HLA Typing or Chimerism Testing?  Hit the Jackpot with GenDx

Wednesday, October 26, 11:45 pm – 13:35 pm

Speakers:

  • Pascal van der Weele PhD, Project Manager R&D at GenDx
  • Erik Rozemuller PhD, Senior Scientist Bioinformatics at GenDx
  • Maarten Penning PhD, Chief Technology Officer at GenDx

Posters 

Our posters will be available online on the ASHI platform.

  • Rapid, robust and reliable high resolution HLA typing of 11 HLA loci using ont minion sequencing (Pascal van der Weele et al)
  • Optimizing gene coverage for HLA class II gene sequencing (Sake van Wageningen et al)
  • Direct vs indirect indexing for NGSBased Chimerism Monitoring (Maaike Rijkers et al)

 

Looking forward to meeting you!
For more information and registration at ASHI, visit https://www.ashi-hla.org/

GenDx to develop NGS-Turbo® following agreement with Oxford Nanopore Technologies

PRESS RELEASE

NGS-Turbo® is a novel rapid high-resolution HLA typing kit aimed at improving transplant outcomes

GenDx today announces that it has signed a non-exclusive service agreement with Oxford Nanopore Technologies (Oxford Nanopore), to bring its new NGS-Turbo® product to the transplant market for high-resolution HLA typing with a turnaround time of less than four hours, enabling improved matching of solid organs in situations where time is a critical factor.
Organ transplantation requires a solid donor organ to be matched to a recipient. Due to time constraints, HLA typing of solid organs such as kidneys is typically restricted to low-resolution results. Nanopore technology allows for high-resolution sequencing in a time period that is suitable for critical organ transplantations. The agreement between GenDx and Oxford Nanopore lifts the 48-hour data processing restriction for commercial software, allowing NGS-Turbo® users to deliver high-resolution HLA typing results to the clinic within four hours after receiving the sample. This contributes to better organ matching and facilitates a better transplantation outcome.

Wietse Mulder PhD, CEO of GenDx, commented: “We are happy that we were able to come to an agreement with Oxford Nanopore. By combining our expertise as a world leader in sequencing-based HLA typing with the sequencing knowledge of Oxford Nanopore, we are convinced that we will be able to bring products to the organ transplantation field that allow better HLA typing, enabling better matching and improved outcome of transplantation.”

About NGS-Turbo®
NGS-Turbo® is one of the latest developments by GenDx. An early access program will start later this year. It consists of a fast amplification of all 11 HLA loci using a whole-gene approach with NGS-Turbo®Amp. After the subsequent extremely quick library preparation NGS-Turbo®Prep, a sample can be sequenced on Oxford Nanopore sequencers and the data can be directly analyzed and typed with NGSengine®. NGS-Turbo is an expansion of GenDx’ current high-resolution HLA typing portfolio.

About Oxford Nanopore Technologies
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

Read the full press release here

Join our training course in September

Training Course – Become an expert in NGS HLA typing

Are you interested in learning about high-resolution HLA typing or expanding your laboratory and data analysis skills? Then our course “Become an expert in NGS HLA typing” is for you! It will take place at the GenDx Headquarters in Utrecht, the Netherlands, in September and includes hands-on laboratory work of the complete NGS HLA workflow and data analysis.

The course includes:

  • Theoretical knowledge of NGS for HLA
  • Hands-on training of multiplexed NGS HLA typing
  • Demonstrating multiple NGS platforms
  • Training on data analysis with NGSengine® through case studies
  • Send your own genomic DNA samples for typing (anonymized samples and data only)

ACHI accredited (1.5 CECs)
Participation fee*: 2.495 EUR (incl VAT)

Register now!

For this training course there are limited spots so make sure to register on time!

After registration, you will receive more information to prepare for the course.

 

*The tuition fee includes 3 hotel nights, drinks, refreshments, lunches, two dinners and all course materials. Travel costs to and from the location are not included and will be at the expense of the participant. 

GenDx licensed cfDNA assay to monitor organ rejection in pediatric heart transplants

PRESS RELEASE

GenDx has obtained a worldwide license from Medical College Wisconsin (MCW) for their patented method to detect donor specific cell free DNA (cfDNA) in pediatric patients that have undergone a heart transplant.

To monitor graft survival, patients need multiple endomyocardial biopsies that are expensive, require anesthesia and are invasive and risky. Researchers at MCW developed a method that instead requires only a small blood sample to monitor transplant rejection. The method comprises a sensitive multiplexed qPCR assessment of the cfDNA donor fraction, which is superior in terms of costs, turn-around time and level of sensitivity. The assay, although developed for pediatric transplant patients, opens a door for broader solid organ transplants as it supports a pan-organ strategy.

Wietse Mulder PhD, CEO of GenDx, commented: “Combining the knowledge of both MCW on cfDNA and GenDx on DNA typing by NGS and real-time PCR in a transplant setting, offers an enormous potential to develop products which can predict early the potential rejection of transplanted organs. We are excited to collaborate with MCW enabling new options for accurate transplant monitoring,”

 

About Cell free DNA

Donor derived cfDNA refers to all non-encapsulated DNA fragments that enter the bloodstream; this mostly happens during apoptosis or necrosis. Analysis of cell free DNA (cfDNA) after solid organ transplantation has been shown to accurately identify and characterize allograft injury and correlate with pathologic findings (e.g. organ rejection).

About the Medical College of Wisconsin

With a history dating back to 1893, The Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,500 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, Green Bay, and Central Wisconsin. MCW’s School of Pharmacy graduated its inaugural PharmD class in 2020. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In the last 10 years, faculty received more than $1.5 billion in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,650 physicians provide care in virtually every specialty of medicine for more than 2.8 million patients annually.

References

Relationship between donor fraction cell-free DNA and clinical rejection in heart transplantation. Deshpande SR, et al. Pediatr Transplant. 2022. PMID: 35258162

 

Read the press release in genomeweb

Read the full press release here

 

IVD registration accomplished for NGSgo®-AmpX v2 and NGSgo Library Full Kit in South Korea

We are excited to share that GenDx received the IVD certificate from the Korean Ministry of Food and Drug Safety (MFDS) for NGSgo®-AmpX v2 and NGSgo®Library Full Kit for single locus amplification in the Republic of Korea.

In close collaboration with Dow Biomedica Inc, our local distributor, HLA labs can now apply this optimized amplification product to obtain high-resolution HLA genotyping information for diagnostic use.

 

BLOG: Together to the Top: the summit

In this blog, we follow the journey of our colleague Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. Henk will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk is the lucky GenDx representative to support the Give&Live cycling club on their way to the top of the mountain. 

June 25, 2022

The alarm goes off at 5.45 AM. It is a chilly morning, but it is sunny and we can see the top of the Mont Ventoux very clearly.

The bakery ‘only’ opens at 07.00 AM, so for those who are leaving extra early, the catering team does a great job at improvising breakfast. They also make sure all bottles, bags and pockets are completely stuffed with drinks, bananas, gels and bars. As if we were going for a 24-hour ride.

Part of the group gets on their bike for the first part to Sault, while part of the group is taken there by car. Once there, another pit stop awaits us to get hydrated and fuel up on some fast carbs. Then, very suddenly, we are given the go-ahead. The start is a bit messy, but eventually everybody is on their bike, on their way to the Mont Ventoux!

The first part goes downhill, which feels a little too easy, but that is soon followed by the first increase. It is difficult to find the right tempo, and it is not easy for the mind to realize that the last part of the climb will be the toughest. Gradually, the tempo gets more comfortable. Everybody needs to find their own tempo. This means that sometimes, others will catch up with you, and sometimes you will be the one overtaking others. You just have to ignore it and ride your own race. One thing is for sure: the buddy will always stay with the athlete. But also the company of other cyclists can be very supportive.

I also notice the many motorbike drivers carrying a first aid kit. On the one hand, this is reassuring, but on the other hand this makes me realize that they are not there for nothing…

We pass another aid station. I make sure to take what I need, because it is easy to overdo it with all there is up for grabs…

The ride gets a bit easier up to Chalet Reynard, which is a little further than half way through. But after this point, it is getting steeper again. By now, you are used to climbing and the determination to push through has kicked in. The environment gets rougher and more barren. The wind gets stronger and the sun is relentless. One more turn, and there it is: the summit is in sight! The photographer is making pictures of the surroundings, and is surprised to see us so soon. He did not expect us to be here already…

We pass the Simson monument; we will only pay it a visit on our way down. For now, the target is locked. A right turn, the summit on our left. They say it will get easier after the next turn, but now we are almost coming to a standstill. It hurts to keep going full force, but you have to, and you can, even without ‘standing’ on the pedals.

A left turn, and then finally… a little less tension on the legs! You hear the people screaming from the top, encouraging you to keep going. In theory, you’ve made it, but not quite yet. There is no way you are giving up at this point! Trying to take the turns in such a way that you are avoiding the steepest parts, keep going, there is no way you are going to get off your bike to walk the last part! One final, very tight, turn to the left… it looks steeper than it is and it takes less effort than expected.

And then there’s the cheering, the time tracking mats, the felicitations… you’ve made it! Unbelievable. Everyone processes it in their own way, with all kinds of emotions. It is extra special to see the family and friends that have been waiting for the athletes to reach the top.

Some cyclists are daring to descend partially, to pick up others and join them on their way to the top. In my opinion, you will always make it as long as you keep taking it slow.

After taking lots of pictures on the summit, we go down again, in small groups. Some by bike, and some by car. On the bike, you easily reach speeds of 30, 40, maybe even over 50 km/hour. It is not possible to hit the brakes all the time. For some, it gets a little too inconvenient, and luckily there’s the option to do part of the descend by car and finish the last part on the bike.

Remember that first part from Sault? That decline? Well, on the way back that is an incline. An incline of 6% that is not necessarily appreciated. Especially since it is quite warm in the valley at this time of day. But… all is good once we reached a nice terrace, with an amazing view of the Mont Ventoux (the greatest view really comes after the toughest climb). The group starts with sharing stories, and won’t stop for the coming days.

We headed back to the base camp. Twelve kilometers, and that final hill with 15% incline. My legs tell me that they have had enough. Now it is time to rest and digest. Good thing there’s a BBQ waiting for us! One of the medical buddy’s mentions: “I do not know if I will be able to bike along next time, but I will certainly join for the food!”

Eventually, everyone has reached their own personal goal today, which was not necessarily reaching the summit of the Mont Ventoux. Even though the journey to the summit was the pinnacle event of this trip to the South of France, the Give & Live cycling group is really about training together and keeping each other motivated to stay fit and healthy.

Henk

BLOG: Together to the Top: the day before and the memorial

In this blog, we follow the journey of our colleague Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. Henk will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk is the lucky GenDx representative to support the Give&Live cycling club on their way to the top of the mountain. 

June 24, 2022

After a good night’s sleep in the cozy cottages, the plans for the day are made and adjusted due to the expected rain, although you wouldn’t say that when you see the Mont Ventoux so bright in the sunlight early in the morning.

Most are sensible, and go for a walk or explore the area, taking a rest day. There’s also a group that decides to cycle up the Mont Ventoux, most of them have done it before. But the weather forecast is not favorable, shelter will have to be taken along the way and that is difficult to plan. Luckily, all return unscathed at the end of the afternoon, cycling in a radiant sun.

A few people were supposed to cycle up the Mont Ventoux today, to put the memorial stones at the monument, but eventually it was decided to do this by car. Fortunately, the weather was kind once they reached the Tom Simpson monument, so that the memorial stones can be laid down in peace and with respect. It is good to think about this for a moment; a successful transplantation is never guaranteed. No matter how hard we try. During the erupting storm, they can drive back to Montbrun, where the catering team barely manages to keep the tents on the ground…

I decide to join the medical buddies today. Because they have to stay with their athlete on Saturday, they cycle their own round on Friday. A total of 4 “cols” will be climbed, 3 of which are above 1000 meters. On the peaks it looks like Autumn: strong wind, later also rain gusts, but when a thunderstorm comes, we must look for shelter. After half an hour we can continue again, cold and wet… a special mountain experience. The descent brings us back to Spring, and we end in a Summery valley. On the top it was only 11 degrees Celsius, in the valley 31…

At a restaurant we only get a little warm again. It is nice to hear the stories of these doctors, how they speak respectfully about patients and the task of supporting them to reach their personal cycling goal tomorrow. How will we do it, where do we expect problems, does anyone need extra help? So, good company and not unimportant: all have good cycling experience in the mountains, today they can learn a lot from them on all fronts.

After dinner, the planning for Saturday is made, a part is taken to the start by bus, most of them will cycle themselves. This evening there is a slightly nervous atmosphere. A last check of the bike, preparing food and drinks, getting the right clothes ready… And then getting to bed early, to get a good night’s sleep for the big day!

Henk

BLOG: Together to the Top: the warming up

In this blog, we follow the journey of our colleague Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. Henk will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk is the lucky GenDx representative to support the Give&Live cycling club on their way to the top of the mountain. 

June 22, 2022

After an overnight bus trip that took about 17.5 hours, we have reached our destination: Montbrun-les-Bains, France. Just in time for dinner!

June 23, 2022

After a very extensive, cyclist-proof breakfast, we are updated on the planning for the day.

Many group pictures are taken: a group of participants who have received a transplant, those who have donated an organ, those who are cycling in memory of a loved one who did receive a transplant but passed away eventually, and a group of medical buddy’s. Finally, we took a picture with all participants, and the GenDx flag.

The rock formations  around us look impressive, a little intimidating even. Especially for those who never biked up a mountain like the Mont Ventoux before. So, today is not only a warming up for the body, but also to prepare the mind.

There are four different routes set out for today, so there is something for everyone. Once all water bottles are filled and the tires inflated, it is time to hit the road! Unfortunately, dark clouds were approaching from the West, which resulted in a cold rain shower. I decided to join the 95 km group and luckily the weather quickly got better. All in all, we will have about 1000 altimeters today. For some, this is a bit too intense, and the group falls apart. In particular for the last part back to the accommodation, a 15% incline, many decide to get off their bike to walk instead. Understandable. After all, we need to save all the energy we need for the pinnacle of this week: a non-stop climb of 1400 meter to the summit of the Mont Ventoux.

Upon our return to the ‘base camp’, we can replenish our energy and make sure to get some extra hydration in. For the cyclists, there’s the option to get a massage to loosen up their muscles. In the meantime, the bike repairman fixes up about 12 bikes, so that they are good to go for the next day.

In the evening, we can enjoy an amazing, extensive, healthy dinner. The catering team is really making sure that we have everything we need (and more). At the dinner table, many stories are shared. Not only about the past day, but also about everyone’s personal motivation to join this journey, and their experiences with transplantation. In these conversations, I recognize that many emphasize the importance of medical care and support. Not only during an event like this one, but basically every day. We also realize that advancement of medical techniques and tools, like the ones GenDx develops, are part of the reason that we are here today, and tomorrow.

Henk

BLOG: Together to the Top: the countdown has begun

In this blog, we follow the journey of our colleague Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. He will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk is the lucky GenDx representatives to support the Give&Live cycling club on their way to the top of the mountain. 

June 21, 2022

Unfortunately, Stefan will not be able to join the trip to France. Nevertheless, Henk will still continue his journey to the summit of the Mont Ventoux, together with Give&Live.

Tecklenburg, Germany (May 29, 2022)
To rise 80 meters in 1 kilometer, slope up to 12%, you first have to go drive about 60 km into Germany to reach Tecklenburg, an old half-timbered town. In a beautiful hilly area, meadows, forests, farmland and rock formations of ancient sandstone alternate. Sunday morning at 10 o’clock, in little drizzling rain, everyone got ready to ride the lap together. There were hardly any flat parts, but we managed to stay together until Tecklenburg.

At kilometer 14, in one move, 80 meters up with hairpin bends, a thrill for some and a swallow for others (“am I going to make it or am I going to stop”), a real test for the ascend of the Ventoux Mountain. People help each other to the top, a push, a technical instruction, encouragement, or helping to place again the chain after a gear error.

Nijverdal’s Mooiste (June 11, 2022)
It was beautiful weather for cycling! Also higher temperatures, which we can use well in training, since it will be warmer in France.
Relaxed location. As always, catching up and making new contacts, because except for the hard core, the composition of the group differs sometimes. Also, because people come from almost all parts of the Netherlands, the distance to be cycled is less of a problem than to travel.

12 cyclists for the 70 km and 12 cyclists for the 51 km tour is a good distribution. The main thing is to keep everything intact ( bike and body ) which unfortunately not everyone succeeded in… There are some cancellations due to injuries or defective bikes, and there is a replacement bike. Soon, a few short, steep climbs are taken, and everyone immediately realizes that things are getting serious! In the end, the intensity of the whole trip was not too bad. We also made a few stops, not that it was really necessary, at least, a flock of sheep on the cycle path, which certainly undermines the average speed…

Cycling over the crest of the Holterberg gives beautiful views on both sides of the hill. At times like these, it is not necessary to go so fast, but if we speed up on the flat parts, it is nice if you are used to riding at 30 km / hour, at least if you want to enjoy the surroundings. A beautiful and varied tour!

A sophisticated and extensive lunch was waiting for us, the right fast and slow carbohydrates were ready with good drinks and even yogurt and fruit. Even the delicious apple cream rolls from the bakery were there again, and they went down just as well as we had cycled. Making final arrangements and looking to the future, what to do after France. Give&Live, but nothing goes without saying! A lot will have to be arranged to keep it running and riding.

On to the Mont Ventoux!

Henk

BLOG: Together to the Top: the GenDx training

In this blog, we follow the journey of our colleagues Stefan Timmerman and Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. They will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk and Stefan are the lucky GenDx representatives to support the Give&Live cycling club on their way to the top of the mountain. 

May 25, 2022

On May 14th, GenDx organized a training for the Give&Live cycling club, in the Utrechtse Heuvelrug area. Both Give&Live members and GenDx employees joined. We started the day with a lunch at restaurant ‘Het Leersumseveld’, after which we hit the road for one or more rounds of cycling.

Bart Valkenburg B.ASc, Technician R&D:
How often do you have the opportunity to meet with people who have had a transplant?
Speak with someone who has donated an organ? To hear what it’s like to be standing on the sidelines? All of this was possible at last GenDx / Give&Live Cycling event.
Joining this event, hearing the stories of these people whilst sharing the same passion for cycling was amazing, both moving and inspiring. Getting to know the individual challenges, but all destined with the same drive and motivation to conquer the Mont Ventoux, I am glad I could be part of this training and share this experience. I am already looking forward to the next event!
Good luck to all the participants, Henk and Stefan riding up the mountain this summer!

Anouk van Tilborg MSc, HR & Communications Associate:
Many personal victories were achieved by the cyclists, varying from biking up their first ever hill, to doing that 6x in a row…
There was only one ‘accident’ in the form of a blown tire, but luckily that happened when the group took a break at the restaurant, not while cycling.
I was very impressed by the personal stories of the Give&Live members, who all have a huge zest for life and their own drive to conquer that Ventoux Mountain this Summer.
It felt like a real reward to see a lot of smiling faces on the day itself, and receiving some ‘thank you’ messages afterwards.
Wishing everybody, including Henk and Stefan, a successful Transplantoux event!
And remember, often the best view comes after the hardest climb, but also don’t forget to appreciate and enjoy the journey.

Anouk

Amsterdam TKI-PPP funding received: Biomarkers for therapy response in Crohn’s Disease; towards a patient-tailored selection

GenDx and Horaizon have teamed up in a consortium led by prof. dr. W. de Jonge from the UMC Amsterdam which has received a 4 years TKI-PPP funding. Goal of the project is to develop a rapid assay to predict therapy response in Crohn’s disease patients.

About the project

Current mainstream therapeutics (“biologicals”), are only partially (<50%) effective and it cannot be predicted which biological will be effective in which patient. This lack of appropriate response to treatment in terms of true clinical remission and healing of ulcerations leads to high cost, and serious adverse events in unresponsive patients. In preceding two-year collaboration, involving 240 patients, the three parties showed that epigenetic markers are highly useful to discriminate responders and non-responders prior to therapy. In this project, targeted epigenetic assays towards markers identified by UMC Amsterdam, will be validated by Horaizon. GenDx will coordinate further development towards a diagnostic kit, to be able to deliver the optimal treatment for each individual Crohn’s disease patient.

GenDx proud sponsor of the IPD-IMGT/HLA Database

GenDx is proud sponsor of the International Immunogenetics Information system (IMGT database), globally used and daily reference for the whole HLA community.

IPD was developed in 2003 to provide a centralized system for the study of polymorphism in genes of the immune system. The IPD project was established by the HLA Informatics Group of the Anthony Nolan Research Institute in close collaboration with the European Bioinformatics Institute.

About the project

The IPD-IMGT/HLA Database (HLA Database) maintains the official sequences for the World Health Organization’s Nomenclature Committee for Factors of the HLA System. For HLA typing laboratories and researchers, the HLA Database is the sole source for validated HLA nucleic acid and amino sequences. These websites, developed and maintained by project leader Professor Steven G.E. Marsh, Chief Bioinformatics and Immunogenetics Officer and Deputy Director of Research, Anthony Nolan Research Institute, are the fundamental tools used worldwide to advance this critical science. The HLA database can be found at: ebi.ac.uk/ipd/imgt/hla and hla.alleles.org.

The IPD-IMGT/HLA Database Website serves as a standard reference resource for the industry with visitors from over 150 countries.

 

For more information please visit https://www.ebi.ac.uk/ipd/imgt/hla/.

GenDx Obtains License for Haplotyping

GenDx obtains a license for haplotyping within transplant diagnostics from Dovetail Genomics

PRESS RELEASE

UTRECHT, June 2 2022
GenDx has obtained a license from Dovetail Genomics to further develop their Micro-C proximity ligation assay. This modern technology will be a new step improving precision to haplotyping of HLA genes. And, as targeted DNA capture is part of the assay, GenDx will combine this methodology with its extensive knowledge of next-generation sequencing (NGS)-based HLA typing to develop highly attractive products.
HLA typing is a method to determine donor and recipient compatibility and is essential for selecting a suitable donor prior to transplantation. Although current HLA typing can be performed with relatively high accuracy, most methods do not provide any information on which HLA genes were inherited together from a single parent. This determination of genes located together on the same chromosome is called haplotyping and is difficult to achieve using short NGS reads because of the long spans of DNA that occur between the genes.
The GenDx assay, based on Dovetail® Micro-C proximity ligation technology, will be able to determine if a donor and recipient carry the same HLA haplotype. When they do, the chances of an extended match (beyond HLA genes) are much higher, which can potentially lead to a better transplantation outcome.

 

Wietse Mulder PhD, CEO of GenDx, commented: “Haplotyping of the crucial HLA genes is currently really challenging. The new strategy offered by the Dovetail Micro-C proximity ligation assay now unveils an outlook of better typing options for the HLA field and we believe that transplant patients will finally benefit from this technology ”.

 

About Proximity Ligation-Based Haplotype Phasing

Proximity ligation approaches have been well known for their ability to capture long-range genomic information. However, they have been unsuitable for genotyping due to significant sequence coverage gaps – traditional approaches miss up to 20% of the human genome. Through re-engineering how the assay is performed, Dovetail Genomics has addressed this shortfall, now enabling SNP phase information to be captured alongside primary genome sequence at coverage levels comparable to or exceeding shotgun libraries. Compatible with targeted enrichment using a hybrid capture panel designed against the 4-Mb HLA region, the technology has been demonstrated to fully capture and phase genetic variation across this entire HLA region.

State-of-art HLA typing analyses rely on comparison of SNP genotyping calls to allele frequency databases to call alleles. Due to the short-range nature of today’s NGS instruments, ambiguity in these calls may exist. Additionally, due to this limited information, it is not possible to resolve parental inheritance. Dovetail’s long-range information inherent to the datatype not only enables more accurate calling for the alleles typed today, but is also capable of fully resolving haplotypes for all genes in the HLA region.

About High-Resolution HLA Typing

The Human Leukocyte Antigen (HLA) system consists of a large family of highly variable genes and many allelic variants which form the basis of the human immunological defense system. In stem cell transplantations, HLA matching of patient and donor is vital, as small differences between HLA alleles may have serious effects on transplantation outcome. High-resolution genotyping is a technology which enables determination of even the smallest variations in HLA genes, making it ideal for stem cell transplantation purposes.

Until recently, Sanger sequencing-based HLA typing was considered the gold standard for high-resolution typing. Today, Next-Generation Sequencing (NGS) has been adopted by the vast majority of HLA laboratories worldwide and has become the new gold standard. This NGS approach offers higher resolution and is more amenable to high-throughput processing.

As one of the pioneering companies in the HLA field, GenDx started offering NGS strategies in 2013, consisting of NGSgo® reagents and the NGSengine® software package for various NGS platforms.
NGSgo®-AmpX was CE marked in 2014, and the NGSgo full workflow compatible with Illumina MiSeq® received the CE mark in 2016. Since 2017, NGSgo & NGSengine are also registered as IVD at Health Canada.

Read full press release here

Important Changes For CE-Marked IVD Products

Changes Under IVDR

GenDx has obtained the CE certificate under the new IVD Regulation (IVDR) for NGSgo® reagents and NGSengine® software (read more about this here).

Although the content of our kits remains the same under the IVDR, there are some important changes regarding:
√ Catalog numbers
√ Kit labels
√ Instructions for use

Changes in catalog numbers

NGSgo-AmpX v2 ● NGSgo-MX6-1 ● NGSengine
Because transitioning from IVDD to IVDR involves major administrative updates, catalog numbers have changed for several products*. Please take note of the following change in catalog numbers:

Although these catalog numbers have changed, the content of these products remains the same.

(*NGSgo-MX11-3 and NGSgo Library Full Kit are also CE marked under the IVDR. Catalog numbers for these products will remain the same, as these products were launched more recently and therefore complied with IVDR from the beginning).

When to start ordering the new catalog numbers?

NGSgo-AmpX v2 ● NGSgo-MX6-1 ● NGSengine
You can start ordering NGSgo-AmpX v2, NGSgo-MX6-1, and NGSengine under the new catalog numbers from June 15, 2022. To allow a transitioning period, ordering under the old catalog numbers remains possible until December 1, 2022. However, we would like to urge you to switch to the new numbers as soon as possible.

NGSgo-MX11-3 ● NGSgo Library Full Kit
We will start shipping NGSgo-MX11-3 and NGSgo Library Full Kit under the IVDR from June 15, 2022. As these catalog numbers do not change, this does not involve any ordering changes for you.

Changes in kit labels

New UDI code
Under the IVDR, product labels will contain a Unique Device Identifier (UDI). This is a barcode consisting of the following parts:
(01) product code (unique for each catalog number)
(10) lot number
(17) expiration date in YYMMDD format, where DD is 00 if day is not specified

You will find the UDI code on the kit labels for unambiguous identification of the kits in order to facilitate their traceability. For NGSengine, the UDI code will be displayed numerically on the splash screen of the software and will include the software version.

New label design

Labels have been slightly redesigned, including re-organization of symbols. New is a link to the location of the electronic version of the Instructions for Use: www.gendx.com/ifu.

Instructions for Use

New IFU versions

There are new versions of the Instructions for Use (IFU) for our IVDR products. The main changes in these versions include an updated intended purpose and additional product information. The laboratory protocols have not changed.
Next to English, these new versions of the IFUs will become available in various other European languages.

No printed IFU in kit

Under the IVDR, we are no longer including a printed version of the IFU in the kit. Instead, you can download the IFU from www.gendx.com/ifu.
If you do need an IFU in paper form, just send a request to support@gendx.com and we will ship a printed copy.

 

Need help or more information?
If you need any help or would like to have more information, please contact us at marketing@gendx.com

GenDx obtained the newest EU Quality Management Certificate (IVDR)

The first company in the field of transplant diagnostics complying with the new IVDR in Europe

PRESS RELEASE

We are very excited to share with you that we received the EU Quality Management Certificate (IVDR) by our notified body Tüv Süd for diagnostic use of our HLA product portfolio. This new IVDR (EU) 2017/746 sets increased standards of quality and safety for diagnostic use of medical devices to ensure the highest level of public health protection.

The IVD Regulation retains all existing IVD Directive requirements, and includes new stringent additional  conditions for in vitro diagnostic devices. Establishing increased quality management, continuous evaluation during the products life cycle and more technical documentation to prove effectiveness are included now. The GenDx HLA portfolio under IVDR contains NGSgo® reagents and NGSengine® software for high-resolution HLA typing. Being one of the first to get certified under the IVDR sets a bench mark for similar products in the field of HLA typing, especially for stand-alone software.

Given the complexity of capturing validation data and building extensive dossiers to obtain IVDR certification, only a few IVD companies have obtained this new certification. The majority of manufacturers is still in the process to implement and prove IVDR compliance for their products.

Therefore, the EU decided recently that, although the effective date of 26 May 2022 remains unchanged, under certain conditions, manufacturers will receive more time to transition to the IVDR. This also applies for GenDx’s chimerism monitoring products, currently CE self-marked under the IVDD.

Wietse Mulder PhD, CEO of GenDx, commented: ‘After a few years of extensive teamwork, we are proud to be the first global supplier in the field of transplant diagnostics, being able to offer a full HLA workflow portfolio under the new IVD Regulation. As a result we can continue to provide our customers with certified products, claiming increased safety and offer improved quality, that will finally benefit transplant patients”.

Read full press release here

 

 

Let’s meet at EFI in Amsterdam

It is almost here!

Only a few days to go! This year we are extra excited as the event is taking place in our home country in Amsterdam, the Netherlands. GenDx is a diamond sponsor this year and we have prepared some special events. Below you can find information about this year’s Teaching Session, Satellite Symposium, and of course register for the famous Tulip Run. We will also be very happy to welcome you and your colleagues to our booth for a software demonstration, any question you may have, or to learn more about our latest products.

Download our program

Register for the teaching session

 

 

18th International HLA & Immunogenetics Workshop

Noordwijkerhout – The Netherlands, May 11-15, 2022

The 18th International HLA & Immunogenetics Workshop (IHIWS) is almost here and we are looking forward to meet you there! The event this year will be held in Noordwijkerhout, the Netherlands, and more than 20 projects will be openly discussed by the project leaders, participants of the projects and workers in the field of histocompatibility and immunogenetics.

The workshop

The first IHIWS workshop took place in 1964 with the goal to bring together the HLA community. It involved scientists from several countries and proved to be a crucial event which led to more extensive collaborations in the following years. More about the history of the workshop can be found here. Nowadays, IHIWS takes place in combination with ASHI/EFI allowing people to discuss and develop tools that would benefit the whole HLA field.  In addition to providing a mechanism for exchanging reagents, the International HLA Workshops have also been promoting new technology and disseminating both reagents and technical skills worldwide. The current chairs of the IHIWS are Eric Spierings and Sebastiaan Heidt.

The database

A lot of interesting subjects are discussed in the workshop, which brought the idea to futureproof the data. Therefore, a database has been set where people are able to share their data with fellow scientists. The whole community can benefit from the IHIWS database. It is a central location when HLA specialists can upload their data and share them. The website will continue being functioning also outside IHIWS times, and project leaders and PIs from labs are 24/7 able to upload their data, making contribution easiest than ever.

GenDx is a proud sponsor of the IHIWS workshop and also provides a developer who is working on the development of the website. GenDx is also supporting several individual participants by providing reagents, software and/or service testing.

Program of the IHIWS workshop

Register to the IHIWS workshop

Visit the IHIWS website

 

Join the GenDx Teaching Session at EFI 2022

Are you also coming to EFI in Amsterdam this May? We gladly invite you to join our Teaching Session and get up-to-date with the recent developments. There is no fee to attend the course, and we welcome all looking to begin or enhance their knowledge of HLA typing by Next Generation Sequencing to register. We are looking forward to meet you again in person!

Register here to attend the live session

 

The training is ACHI accredited:1,2 continuing education credits (CECs) or 8 contact hours. For any question or for more information, contact education@gendx.com
We are looking forward to seeing you in person soon!

 

Registration of the GenDx portfolio as IVD in Canada, Serbia, and Malaysia

GenDx, has received the medical device license from Health Canada for in vitro diagnostic use of NSGgo®-MX11-3.
NGSgo-MX11-3 provides multiplexed genotyping of 11 HLA loci with incredible speed and high accuracy, contributing to the success of stem cell transplantation. In addition, NGSgo-MX11-3 offers the highest available gene coverage of any HLA multiplex strategy on the market.

This is the third NGS assay GenDx has registered in Canada as IVD, following NGSgo®-AmpX v2 for genotyping of 11 individual HLA genes, and NGSgo®-MX6-1 for multiplexed genotyping of six HLA genes. The amplification aims to obtain high-resolution HLA genotyping information by means of downstream sequencing applications with Illumina MiSeq®, and genotype analysis with our IVD-registered NGSengine® software.

By obtaining the Health Canada license, GenDx completes registration of the NGSgo® product line. This line encompasses the first IVD products in Canada that employ NGS-based HLA typing and is suitable for diagnostic use. This product line enables better matching of donors and patients in need of a stem cell transplantation.

Wietse Mulder PhD, CEO of GenDx, commented: ‘we are proud to be the first supplier in Canada that can offer a broad range of IVD registered NGS products for the transplant community. Now, users can pick their own amplification preference. This latest addition of MX11-3 fits into the trend of applying multiplexed amplification and sequencing of 11 HLA genes of every patient and donor in a single run’.

Read full press release in Genomeweb here

Other IVD registrations

In Serbia, with the help of our Serbian distributor,Jasika d.o.o., we can now offer the entire NGS family, represented by NGSgo-AmpX v2, NGSgo-MX6-1, NGSgo-MX11-3, NGSgo Library Full Kit, and NGSengine for diagnostic purposes.

In Malaysia, together with our distributor Stem Molecular Diagnostics Sdn Bhd, we completed the registration for NGSgo®-MX6-1 and NGSgo® Library Full Kit which can from now on be offered also as IVD.

 

NGSengine now also in French, German, Italian, Spanish

NGSengine® has been updated

Version 2.25.0 includes new features and improvements, and the IMGT/HLA database 3.47. We are also excited to share that from now on, the user interface is also available in French, Spanish, German, and Italian.

Update now!

Make sure to update your software to the latest version to have access to the new features and the latest database. For a complete overview of all changes, please check the release certificate.

Download NGSengine 2.25.0

NGSengine release certificate
NGSignition release certificate

You can find the latest NGSengine IFUs here (CE, Edition 12) and here (RUO, Edition 12), and the latest NGSignition IFU here (Edition 6).

We are growing and expanding our office and lab space

 

GenDx and Stichting Incubator Utrecht have signed a rental agreement for the top three floors of the Alexander Numan Building. GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors and since 2006 expanding gradually with more office and lab space.

To accommodate 75+ employees today and provide room for R&D, IVD production and logistics, another enlargement was required again. In addition to the 3rd floor, GenDx will get about 3000m2 at its disposal as a welcome replacement for the currently used office and laboratory space in the Androclus building.

Having all activities in a single building with an own conference room and catering will ease collaboration and offer room for further expansion in the near future. As soon as the current tenants have moved to the Accelerator building, GenDx will start adjusting the facilities and expects to be fully operational in the first quarter of 2023.

 

Read the full press release here

Product update
NGSgo®-AmpX KIR

We have improved our NGSgo-AmpX KIR kit, which includes a few protocol changes to benefit the robustness of the protocol.

This change will take effect from your next order (kit lot# 22000148 and up). Individual primer tubes can be recognized by the indication of the no. of reactions on the tube label instead of the previous dissolving volume.

What has changed?

√ Primer resuspension volume increased from 27 to 40 µl.
√ PCR reaction volume increased from 10 to 15 µl.
√ Elongation time of the cycling protocol increased from 8 to 14 min.

Updated Instructions for Use

You can find the changes in edition 4 of the Instructions for Use, which is to be used with NGSgo-AmpX KIR kit lot# 22000148 and up.

Download here

Need help or more information?

You can find more information about our KIR products here.

Do you have additional questions? Our support team will be very happy to assist you!

New Collaboration UMCU & GenDx for NGSgo ONCOdentify® MPN

Benefits

  • Hemato-oncology diagnostic assays
  • Targeting leukemia molecular markers

Description

In collaboration with University Medical Center of Utrecht (UMCU), GenDx has added a new assay to its product portfolio which is tailored for detecting genetic markers in blood cancers. NGSgo ONCOdentify® identifies mutations within the JAK2, CALR and MPL genes, valuable for the prognosis and selecting treatment options for myeloproliferative neoplasm (MPN).  In the coming period, UMCU will validate these new assays in their routine laboratory work.

The MPN kit is the first of a series of assays to detect somatic mutations related to hematological malignancies like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL). The test can be used on Illumina sequencing platforms.

Next generation sequencing (NGS) offers advantages in accuracy, sensitivity, and speed with the potential to significantly impact the field of oncology. Because NGS can cope with a multiplexed approach of genes in a single assay, it reduces the number of multiple tests as an efficient and fast way to identify the causative mutation.

Wietse Mulder PhD, CEO of GenDx says: ‘Anchored on extensive knowledge of developing software and reagents for accurate HLA typing, we can now offer NGSgo ONCOdentify as a highly sensitive assay for detection of mutations in a tumor sample. We are convinced that this assay is a valuable contribution to improve tailor made treatment of blood cancers. ONCOdentify is now launched as Research Use Only (RUO), but we are in the process of validating it for In Vitro Diagnostic (IVD) device’.

Interested? Contact us for additional information, we will be happy to answer your questions! The product will become available for sale in the coming year.

 

Find the complete press release here

Join our virtual training course in February

GenDx is organizing a virtual training course to help you become an NGS HLA typing expert in just 3 mornings.

The course will start with the basics of NGS HLA typing and move up to an advanced level. They include the theoretical background of NGS, a practical workflow demonstration via videos, and extensive NGSengine software training.

So, are you interested in expanding your knowledge of high-resolution HLA tissue typing?

Register now, limited seats available:

Become an expert in NGS HLA typing , February 23-25, 2022

Stay up-to-date on all our educational events by frequently checking our website: GenDx.com/education.
If you have any questions, please contact us directly via education@gendx.com.

in memoriam

Prof dr. Hidetoshi Inoko

★ 4th of January 1948 – † 3rd of January 2022

Recently the sad news reached us that Prof. Hidetoshi Inoko has passed away. Professor Inoko was a pioneer in unravelling the genetic complexity of the MHC region at a time that the current methods for genetic analysis were not available.
Later he was involved in all aspects of MHC, such as evolution, anthropology, diversity disease association and transplantation.
He also had major functions and important influence in the HLA society.
Prof Inoko was a great inspiration to both of us which we will cherish.

Wietse Mulder and Erik Rozemuller


Message from American Society for Histocompatibility and Immunogenetics: 

It’s with sadness that we inform you of the passing of Hidetoshi Inoko. The following tribute was written by Seiamak Bahram and John Trowsdale.

In this age it is easy to forget just how tortuous analysis of human immunogenetics used to be but in fact most of the fundamental discoveries about the MHC  genes were made before high throughput sequencing came onstream. Hidetoshi Inoko recognised the value of large-scale structural analysis of the MHC region, in man as well as other species, in the 1980’s and was a great contributor to the advancement of our field before he contributed to the first sequencing of the complex in 1999. From 1990 he was an early adopter of DNA typing for histocompatibility. The other approach he exploited for disease mapping on a genome scale was that of polymorphic microsatellites, which led to one of the very first Genome Wide Association Studies (GWAS) ever performed, that of rheumatoid arthritis using over 27000 microsatellites, a major tour de force at the time (2005).

From 1966 to 1976 Professor Inoko did his BSc and PhD (Science) degrees at Kyoto University, followed by eight years at Keio before moving to Tokai in 1984. He spent a year in Trowsdale’s laboratory in London at Cancer Research UK (then ICRF) in 1986-7 and qualified for a PhD in Medical Science in 1987. He became a Professor in 1992. His leadership qualities were recognised as he was elected Chairman of the Department of Molecular Life Science in Tokai University’s School of Medicine in 1993 and Vice-Dean in 2000, followed by Dean of the Graduate School in 2002 and then of the School of Medicine in 2006, when he was also director of the Institute of Medical Sciences. In 2021 Hide become Project Professor of the Center for iPS Cell Research and Application (CiRA) and Emeritus Professor of Tokai University in 2013. He co-led, in the past 10 years, with Seiamak Bahram, the only French-Japanese joint INSERM-JSPS laboratory, focused on histocompatibility.

Professor Inoko was a Councillor for the International HLA and Immunogenetics workshops and he played a major role in several of these successful large-scale events as well as in the Asia-Oceania Histocompatibility and Immunogenetics Workshops. He was also President of the Japanese Society for Histocompatibility and Immunogenetics. A committed educator, he was a visiting lecturer in several Japanese Institutes as well as abroad.

As a work colleague Hide was unique, a friend larger than life. He enjoyed the pleasures of international travel, of companionship as well as Scotch whiskey and red Burgundy. He was also an avid golf player. Many of us were recipients of his generous hospitality and kindness in hosting visitors in Japan where he was active 18 hours a day to make sure his guests experienced the best of Japanese culture. Hide worked and played extremely hard and was always cheerful and open-minded.

Seiamak Bahram and John Trowsdale

Registration of the GenDx portfolio as IVDs in Belarus


This week we have received the registration certificate from the Ministry of Health for the registration of the leading products of GenDx as IVDs in Belarus.

In close collaboration with our Russian distributor BioChemMack, we can now offer the entire NGSgo® family, represented by NGSgo-AmpX v2, NGSgo-MX6-1, NGSgo-MX11-3 and NGSgo Library Full Kit, for diagnostic purposes in Belarus.

Of course, the AlleleSEQR® product line for Sanger sequencing is still available as IVD as well.

Letter from the CEO

Together with you, we are starting this new year with confidence and great expectations.

We just want to say a big thank you for your continued trust and collaboration in 2021, yet another challenging year, but filled with big accomplishments. Although the battle against COVID-19 is not over yet, nor are our lives back to ‘normal’, we have found new and successful solutions to keep in touch and collaborate remotely.

We took use of the power of the online world and realized we had to connect even stronger than before. We hosted a record number of webinars, virtual education sessions, and online demonstrations. Meanwhile, our R&D team achieved several milestones with respect to our product portfolio which will ease your lab activities.

The future ahead

In 2022 we expect to develop more innovative products, contributing to the best possible performance for our users. Be prepared for news about usage of our products on several NGS platforms and the possibility to obtain results within a day. Paired with the continuous improvement of our online activities, we are optimistic that we can attend meetings in person and get to be truly present once more. Obviously, we will continue to strive for excellent customer support, answering any questions that may arise.

Very good news is the expected IVDR compliance and registration which will be valid from May on, also being a strong quality argument for our products in non-European Countries. We are also excited to extend our product portfolio from its solid NGS base for efficient multiplexed HLA amplification and chimerism monitoring. In addition, the interest for HLA-loss is a huge pacesetter for post-transplant monitoring, either by NGS or PCR. And our renowned NGSengine® software will be your key to uncover blood group typing.

Our USA customers and contacts will benefit from a larger GenDx team set up in Chicago and we are all thrilled to meet a lot of you during the EFI2022 conference in May, happening in Amsterdam in our home country. We secured a premium spot as GenDx is the single diamond sponsor of this meeting. Stay tuned for our educational activities and not to forget: the renowned GenDx Tulip Run.

We are starting this exciting new year with a driven focus on excellence and as always we look forward to continue our collaboration with you to advance the field of transplantation and support the HLA community.

Stay safe and we wish you a successful Happy New year!

 

 

Sincerely,

Wietse Mulder PhD, CEO

Holiday closure

Please note that GenDx will be closed from December 24, 2021 to January 3, 2022. Make sure to place your order before December 20 (within Europe) or before December 13 (outside Europe) to get your order processed this year. Orders received after this date will be shipped in the week of January 3 (within Europe) or in the week of January 10 (outside Europe).

We wish you a wonderful holiday season and a successful new year!

Discover our NGS approach for chimerism monitoring

Genome Diagnostics B.V., also known as GenDx, is now launching NGStrack® and TRKengine®, its newest RUO (Research Use Only) marked reagents and software for chimerism monitoring by NGS (next-generation sequencing). This method can be used as an alternative for the current conventional STR (short tandem repeat) technique, with NGStrack being significantly more sensitive. NGStrack provides reliable chimerism data, at both high and low percentages.

NGStrack makes use of 32 so-called indel markers to distinguish between donor and recipient, based on inserted or deleted DNA fragments. Together the 32 indels cover 362 distinctive nucleotide positions across 18 chromosomes, including X/Y chromosomes. Only minimal amounts of DNA are required from the pre-sample, since it only needs to be tested during the initial step of determining informative markers. This prevents a potential run out of pre-sample DNA during the monitoring phase.

TRKengine software interprets the informativity of the markers and quantifies the chimerism percentage in post-samples. Its use as data management system allows for insightful chimerism monitoring and trending over time.

The NGStrack markers overlap with the existing GenDx qPCR kits for chimerism monitoring (KMRtype® and KMRtrack®), therefore it is possible to use both methods in parallel. NGStrack reagents and TRKengine software are compatible with Illumina sequencing platforms. As such, NGStrack can easily be included in our renowned NGSgo® workflow that has been successfully used in HLA labs for many years.

Dr. Wietse Mulder, CEO of GenDx, commented: “We are thrilled to offer these products to the market, enabling users to combine their routine NGS for HLA typing with chimerism monitoring. As of today, the field has the choice to replace conventional STR by a far more efficient and effective technique!”

 

Ready to start chimerism monitoring by NGS? Contact us for additional information, we will be happy to answer your questions!

Read more about NGStrack and TRKengine here

Find the complete press release here

GenDx appoints Cornell University Ass. Professor Iwijn De Vlaminck as Scientific Advisor

GenDx is excited to announce the appointment of Ass. Prof. Iwijn De Vlaminck as Scientific Advisor. De Vlaminck is renowned for his extensive expertise with cell-free DNA/RNA detection, which can be applied to new groundbreaking methods, including monitoring the outcome of transplantation.

Dr. Iwijn De Vlaminck joined the faculty of the Meinig School of Biomedical Engineering at Cornell University in 2015. His research at Cornell focuses on the development of precision medicine technologies for the monitoring of infectious diseases and immune related complications. De Vlaminck obtained a PhD in Science and Engineering from the KU Leuven in Belgium. He received postdoctoral training in the labs of Stephen Quake at Stanford University, USA and Cees Dekker at the TU Delft, The Netherlands. He was awarded the NIH Director’s New Innovator Award in 2017 and the Robert Noyce Assistant Professorship in 2015.

De Vlaminck’s research focuses on the development of molecular analysis technologies for microbiology and immunology and the application of these technologies in the monitoring of infectious diseases and immune-related complications. His research is highly interdisciplinary in nature, resulting in innovative applications in genomics, computational biology and molecular engineering. GenDx expects that his knowledge of cell-free DNA as an upcoming biomarker in transplantation will be of great importance for the development of cutting edge products improving transplantation outcome.

With De Vlaminck, the Scientific Advisory Board of GenDx exist now of four top level qualified members (Em. Prof. John Trowsdale PhD, Prof. Seiamak Bahram PhD and Em. Prof. Frans Claas PhD), covering the fields of precision medicine technologies, MHC immunogenetics, non-conventional histocompatibility genes, blood groups, immunohematology and blood transfusion.

Dr. Wietse Mulder (CEO of GenDx):

“We are extremely honored and delighted to have Iwijn De Vlaminck in our scientific advisory board. His knowledge and view on the HLA lab of the future, also recently shown during the annual ASHI meeting in Orlando, will be extremely useful to enthuse our R&D team further. I’m looking forward to jointly develop new strategies which we expect that these will contribute to the quality of life and survival of transplant patients”.

CRISPR diagnostic company Scope Biosciences raises €1M funding in a partnership with GenDx

WAGENINGEN, 29th October 2021 – Diagnostic startup company Scope Biosciences B.V. has raised €1M funding from Utrecht based GenDx, specialized in Next Generation Sequencing (NGS) products for transplant diagnostics.

Elaborating on the work of Dutch Spinoza-winning scientist prof. dr. John van der Oost and ass. prof. dr. Raymond Staals at Wageningen University, Scope Biosciences applies CRISPR-Cas’ inherent specificity and ease of use to develop a molecular diagnostic platform. This will revolutionize the field of diagnostics as the simplicity of the assay promises to bring highly accurate molecular diagnostics outside the research laboratory like clinical bedside applications.

Scope Biosciences will benefit from GenDx’ experience to speed up developing and marketing the ScopeDx platform. Furthermore, Scope Biosciences plans to use the funding to grow its research and development team, and expand on the running partnerships in the development of rapid diagnostics for infectious diseases in healthcare, veterinary and agri-food applications.

The collaboration with GenDx is mutually beneficial, as it will entail a co-development trajectory to develop ScopeDx applications for transplant diagnostics.

Dr. Wietse Mulder (CEO of GenDx):

“We are excited to collaborate with such a motivated and energetic team of Scope Biosciences that is supported by WUR, the renowned scientists Van der Oost and Staals and the seasoned businessmen Math Kohnen and Wil Hazenberg. We truly believe that together with them both Scope Biosciences and GenDx will be able to deliver meaningful products to the field of diagnostics based on CRISPR-Cas technology.”

Niek Savelkoul (CEO of Scope Biosciences):

“The proprietary ScopeDx CRISPR-diagnostic platform has shown its incredible potential in various applications in the last 3 years of its development, and with this investment we can bring the first ScopeDx products to the market. We are delighted to see such excitement from GenDx who recognize the potential of the ScopeDx platform technology. We are looking forward to working with and learning from this leading provider of transplant diagnostics.

GenDx at ASHI 2021

The hybrid event took place from September 27 to November 1. We were very happy to see that many of you got in contact with us either in person or in our virtual booth, showing a lot of interest in our products, thank you for that! Some of our materials from the event are now available online and can be found in the links below so feel free to check them out!

Posters

The posters that were presented are now published on our website. Make sure to check them out and get updated with our latest developments. GenDx posters at ASHI 2021

User group meeting

In this year’s UGM we shared with you:

  • our latest development on Chimerism monitoring by NGS
  • exciting preliminary results of our platform comparison study where long read data from Pacbio and MinION are compared to short-read data
  • an update on our newest multiplex strategy NGSgo-MX11-3

For those who have missed it, video is now available upon request

Tulip Run

Last but now least, the Tulip Run. It was great to be able to run live with you again! On our Tulip Run gallery, we now share the photos of the event: Tulip Run ASHI 2021

Until next year at the ASHI 2022 in Las Vegas!

HML exporter available in NGSengine® 2.23.1!

NGSengine has been updated!

We have released the new version of our NGSengine software. Version 2.23.1 includes several new features and improvements, and the latest IMGT/HLA database 3.45.1.

HML exporter now available

To facilitate the digital reporting of HLA testing results and the collection of the raw probe, primer, and sequence data, the NMDP Bioinformatics group developed a software reporting format in 1998 but maintenance and extension became increasingly difficult due to the rigid format limitations. Therefore, the NMDP Bioinformatics group developed an XML-based reporting format to address the shortcomings of the previous format. The XML-based format is called Histoimmunogenetics Markup Language (HML) and is intended as a potentially general-purpose format for exchanging genetic typing data.

From the version 2.23.1 of NGSengine onwards, you will be able to export the typing results also in HML format. This has been a long-awaited feature as HML is the format of choice to upload data in the IHIW 18 workshop, to which GenDx is a sponsor and official partner. Now any user of NGSengine will be able to create a .hml file and contribute to the database maintained by the workshop promoting research, science, and exchange of valuable data.

Interested?

For more information regarding the HML format check the publication “Histoimmunogenetics Markup Language 1.0: Reporting next generation sequencing-based HLA and KIR genotyping” or directly contact us at marketing@gendx.com

Download NGSengine 2.23.1

 

New NGSengine tutorials now available!

New NGSengine tutorial videos are now available on the GenDx website in the Education section. Are you a new NGSengine user and want to become familiar with the software? Or are you an experienced user in need of a refresher or some extra help? Watch our videos and become an NGSengine expert!

The videos include all the latest features of NGSengine, as well as updated graphics that make the videos easier to follow.

Enjoy!

Watch the new instructional videos

Interview with stem cell donor Gerben Cramer

Gerben Cramer is a 25-year-old student, currently enrolled in the master’s program ‘Public Sector Management’, and living in Leiden, The Netherlands.

In the summer of 2020, Gerben did something extraordinary: he donated his stem cells to an anonymous patient. We wanted to learn more about what it can be like to be a stem cell donor, and were happy to get in touch with Gerben. Enjoy reading!

When and why did you decide to register as a stem cell donor?
In January 2020, a good friend of mine sent a message in a group WhatsApp, sharing the story of a friend of his, who underwent a stem cell transplant as a treatment for leukemia. The road to receiving the transplant was a bumpy one, as the initial stem cell donor cancelled last minute. As a result, they had to consider finding an eligible donor within the family. The mother turned out to be the best fit, but given her age, it was a risky procedure. Fortunately, the transplant went well, and the patient survived. My friend concluded his story by saying: “Guys, please consider registering yourself as a stem cell donor, because my friend is luckily still alive, but there are still so many patients looking for a stem cell donor.” For me, this message was reason enough to sign up. I joined the registry the next day.

“For me, that message was reason enough to sign up. I joined the registry the next day.”

You were not registered for that long when you got the call?
Indeed! I was pretty surprised that Matchis reached out to me in March 2020. I did not expect to hear from them so quickly. They told me that it was indeed very unusual, but at that moment there was someone, somewhere in the world, in need of a stem cell transplant… and I was one of the five potential donors selected from the database. So then they examined my blood, and there was a more in-depth medical examination, questions about daily life, and my motivations. In the end, I turned out to be the best match for the patient.

What went through your mind when you heard that you were the best match?
Well, they asked me “Are you sure? Are you sure that you want to do this?”. I did not really understand the question, because I thought “Of course! There is a match, and I read that there’s only a 1 : 50.000 chance that you are selected as donor”. What was on top of mind for me, was that if I could help someone, I should do it. I found it amazing that I could do it, so I thought let’s go! Of course, I was also a bit nervous, but mostly I was grateful that I got to be the one to do this.

What do you think about the way you were informed about the procedure in general and the associated risks?
The guidance from Matchis was super good. They really took the time, checked in on how I was doing and how I felt about things, and were honest about the procedure and potential risks. Right from the start, a buddy from Matchis was assigned to me. I could really ask her anything, and she was there on the day of the transplant. That was really nice! They also arranged for a taxi to pick me up and get me back home. Everything is very well organized. Of course you are making an effort by being a donor, but still. It feels like a token of appreciation; they are happy that you are willing to do it.

Was there anything in particular that you were nervous about?
Yes, I was nervous about certain side effects. Personally, I was happy that my stem cells were taken from my blood, as there are less side effects associated with this method than donation via the bone marrow. But, in my opinion, the risk comes with the job, and I wanted to do the job.

Who decides whether stem cells are taken from blood or bone marrow?
You can indicate your preference, but eventually it is up to the patient’s doctor which method will be best for the patient. For example, for very small children, a stem cell transplant via the blood is more invasive than via the bone marrow. For older patients, the majority of transplant procedures are in the form of a blood transfusion.

What did the donation procedure look like? And how did you experience it?
72 hours before arriving at the hospital, you have to start with injecting a growth factor drug, to stimulate the body to make more stem cells. Someone from home health care (thuiszorg) came to my house to explain everything. The growth factors needed to be injected in my belly twice a day and fortunately my friends were willing to help me as it felt a little strange doing it myself at some point. Luckily, I did not experience too many unpleasant effects, whereas others do experience muscle and back pain. I was happy to start the donation relatively fit.

On donation day, 09.00AM, I arrived at the hospital. I took a seat, needles were injected in both arms, and then they started the transfusion; three rounds in total.

I found it a bit hard not to know the person for which I was doing this. It was someone, somewhere in the world, but that was all I knew; it remains anonymous. At some point during the day, they told me the patient’s gender and age. Also, I learned that the patient was on the heavier side, which meant that he needed more stem cells than the average person. So, it depends on how many stem cells are required for the patient whether the donation takes shorter or longer. For me, it took until 5.00PM.

My body had been working the whole day, and you basically ‘loose something’, so I was pretty exhausted.

“Only when I heard the good news about the patient doing well, it all felt more ‘real’ and personal. That’s when it really kicked in”

What was the donation like, on a more emotional level?
During the donation, I felt a little bit ‘distanced’ from the cause; you are laying there and at the end of the day, a courier comes along to pick up the stem cells. When I got back home, sitting on the couch, I really felt how tired I was. I could not tell too many people about the transplant, because of anonymity measures. Also, donor and patient can send each other a message, post donation, but that is all anonymous, so for all you know he might live as far away as Madagascar, or something. So, I just continued my life as normal, while I expected that what I just did would feel more special, but that was not really the case.

Only when I heard the good news about the patient doing well (6 months after the donation), it all felt more ‘real’ and personal. For me, it was at that exact moment that it ‘kicked in’. I do not mean this in an arrogant or selfish way, but I realized that the patient survived, because of MY stem cells. That felt so special.

“If I get the chance to make a difference again, I would do it. Without a doubt.”

Would you do it again? What if you turn out to be a good match for someone else in need?
Yes. Without a doubt! I have told my story to many others, hoping to inspire them to register as a stem cell donor as well, and if I get the chance to make a difference again, I would do it.

Let’s go!

Actually, after the donation, I was asked whether I would be willing to donate more stem cells or white blood cells for the patient, when needed. And of course I said ‘yes’. Typically, something like this would happen about 3 months after the donation. It didn’t happen eventually.

How long did the recovery process take for you?
Not that long, actually. Two days, max. But other than feeling tired, I did not experience any side effects. For the first 6 months after the donation, they make sure to check how you are doing on a monthly basis. After that, only every 6 months, and at a certain point it’s once a year. This way they can monitor whether there are any late side effects occurring after the donation. I definitely appreciate that they are checking in on me!

What would you like to say to people who are not sure if they want to become a potential stem cell donor? For example, people who are a bit scared of the procedure?
I can only speak from my own experience. I think it is most important to inform people, and I feel honored to be able to share my story and information on stem cell donation. Still, to be honest, sometimes I think: “Come on! There are patients, with leukemia for example, waiting for a stem cell donor. Just do it! You can potentially save a life!”… But even though I think everybody should sign up, everyone eventually has to make their own decision.

“The choice is yours, but actually you should just do it”

I really would like to say that the guidance from the Matchis foundation throughout the whole trajectory is absolutely superb. They are very professional and they really show their appreciation for the donors. I experienced that every nurse, every doctor, they all said “Thank you”, so I felt really valued. On the one hand, you are doing something really significant, and on the other hand, it is such a small effort… There is only a small chance that you are matched with a patient, but when you get the call, you can give a chance at life!

That is a beautiful conclusion. Thank you so much for sharing your story, Gerben!

———

Are you inspired to become a stem cell donor and give someone a chance to live? Go to www.GenDx.com/stem-cell-donation/ to learn more about how you can register.

 

 

 

Interview with two-time cancer survivor Frans Paymans

Frans Paymans (61) is a former professional soccer player and a two-time cancer survivor.

He got diagnosed with non-Hodgkin’s mantle cell lymphoma in 2011. Back then, Frans was treated by means of his own stem cells. Unfortunately, the disease came back in 2016, and thanks to a match with someone from the stem cell donor registry, Frans was able to recover from the cancer. The battle was not over yet, due to graft-versus-host disease. This implies that donated cells (the graft) see the recipient’s cells (the host) as foreign and attack them; a reverse rejection so to say. Luckily, Frans fully recovered from this as well, and was able to go on. Nowadays, Frans is working as location manager on a school for special education. He is committed to keep raising awareness on the importance of stem cell donation, and associated topics.

“Eventually, it comes down to luck, and I have been extremely lucky!”

When were you diagnosed with cancer for the first time?
In 2010, I went to see a doctor after discovering a bump in my inguinal area. That turned out to be a swollen lymph node. In June 2011, I was diagnosed with non-Hodgkin’s mantle cell lymphoma, which is a relatively uncommon type of cancer that affects the lymphatic system and damaged about three-quarter of my bone marrow. By the end of July 2011, the treatment started at the Radboud University Medical Center in Nijmegen, The Netherlands. The first stem cell transplant was on January 24th 2012, and those were my own stem cells.

Wait… what? Your own stem cells?
Yes, my own stem cells! It is called an ‘autologous’ stem cell transplant. The procedure is similar to when a donor goes through the donation process, involving growth factor drug injections to stimulate stem cell production. I first received chemotherapy, and that basically destroys your body, so I had just enough healthy stem cells that could be filtered out and collected by means of an apheresis machine. Eventually, your own stem cells are returned to the body through infusion. It cured me, but unfortunately the cancer came back completely in 2016.

What was the treatment like the second time around?
They went looking for a donor and, luckily, they found a very good match in the stem cell donor database; a young woman from the United States. Our blood group and HLA matched perfectly for the purpose of a stem cell transplant. Thanks to her donation, which was on October 10th 2016, I received the stem cells on October 11th 2016. I recently had my final check up with ‘my’ doctor. She and her team have been of unbelievable value. From now on, I only need to visit the outpatient department with longer intervals. They still need to monitor you, as there can potentially be residual effects from chemo, even after 10 years. Other than that, all is well.

How did you experience receiving stem cells from someone you do not even know?
I was pretty naïve at first, as I thought that getting stem cells was ‘as easy as buying a bread from the bakery’, but that turned out not to be the case… I was extremely lucky to match with a donor from the registry, and that donor is the reason I am sitting here, having this conversation with you, and the reason I can do everything I want to do.

And that’s why, a couple of years ago, when I was sitting on the top of a mountain in Norway, with my wife, I decided to share my story by publishing a book. A book about 60 years on this earth, and what it all meant to me and what it has brought me. And the ultimate goal was to donate part of the profits to Matchis and KWF Dutch Cancer Society.

The book is titled “It is a Competition” (Het is een Wedstrijd). What was it like to write that book? And, If I may say so, I get the feeling that to you, the battle has not yet ended…
It was a nice thing to do, but it was also very confronting, both regarding the period I was sick and the period prior to that. My main motivator to write this book was the thought of all those who do not live to tell about it.

And yes, on the one hand the battle is over, as last year I was able to leave quite some things behind me. All that’s left, is the possibility of residual effects from the chemo therapy that I had back in 2011. But, on the other hand, there is still a need to increase the chances for others to find their perfect match, that battle will never be over. I am committed to raise as much awareness about the topic as possible, and I really want to motivate people to register themselves as a stem cell donor at Matchis.

Looking back to the moment you just got the diagnosis. You told me that you did not know what you were up against at first. How did you cope with that? And what were your first experiences during treatment?
Well, my wife is a nurse and she pretty much knew what was coming, but initially, I had no idea what I was up against. After the diagnosis, driving back home in our car , there was an item on ‘Alpe D’HuZes’ on the radio. That was the first time I truly realized what that initiative was for, and that really hit me hard. When we got home, we first had a good cry. Then, the questions started coming: “What does this all mean? Am I going to survive this? Will I live to see my grandchildren?”. My wife and I met in 2010, and in June 2011 I got the diagnosis, so we had not been together for that long. We wrote down all our questions, and contacted my doctor, who was willing to discuss everything we wanted to know. What I really appreciated, is that she was transparent and straightforward.

At some point, after chemo started, I woke up looking at my pillow covered with plucks of hair that had fallen out. I realized at that moment that this was a first tangible result of the chemo. I had a couple of outpatient treatments, but at some point I was in the hospital for about 78 days, divided over 3 hospital admissions. Both the treatment and recovering from the treatment was, to put it mildly, not always the most pleasant experience. Basically, all that’s left is a body with a beating heart. You feel exhausted. You do not have any energy to do anything, not even to take a shower in the morning.

“Basically, after chemo, all that’s left is a body with a beating heart. You feel exhausted.”

Would you say that your athlete mentality benefited you throughout the whole trajectory?
Yes, I definitely think that my love for sports helped me back then, and that motivated me to get on the home trainer at least 2 and sometimes 3 times per day, for about 15-20 minutes. I did this to keep myself busy, but was also hoping it would contribute to my recovery. Still, eventually it comes down to luck, and I have been extremely lucky.

Actually, around the time I got my first treatment, in 2011, they started with research regarding the effects of working out prior to cancer treatment. I believe that nowadays, health insurances are covering costs for personal training for people who need to get treatment so they will start at a higher fitness baseline. So, that is a beautiful development, if you ask me.

What else helped you to get through the treatment and recovery?
My wife. She was there for me. You really need that ‘second person’ to be there during meetings with the doctor, as you are only able to process half of what they are telling you. The role of the partner is extremely important, and sometimes even underexposed. Imagine what they are going through: keeping their day to day life running, commute to and from the hospital, worrying about you and going to bed alone, scared that you might not be there anymore when they wake up the next day…  That is extremely hard and I think there should be more awareness about this as well.

Also, what I remember very vividly, is something that happened in 2012, when I was doing extremely unwell. My old soccer team, N.E.C. Nijmegen, played against my favorite soccer team, Feyenoord. There was a gigantic banner, put up by the crowd in the stadium, that said: “Frans, keep fighting” along with a huge painting of my face. It touched me deeply. I got so many messages after that. The original banner is completely weathered by now. To my surprise, the boys who made the original banner gifted me a small replica, on canvas, a short while ago. That was heartwarming.

I learned that it is possible to send an anonymous letter to the donor. Did you do that?
Not yet… it did cross our minds many times already, but it wasn’t the right time. In October 2021, it will be exactly 5 years ago that I got the stem cell transplant, so we are planning to send the letter then. A short while ago, during the “Stamweek”, I got the chance to read out loud part of the letter to my donor, live on radio station 3FM. That was very special.
The people from Matchis and the Radboud UMC stem cell consultants will be translating the final letter for me, and make sure there is no information in it that can be traced back to me. They will then send the letter to my donor.

Why did you decide to wait for the five year mark?
Things can still go wrong. And for me, it did. When I was finally cured from cancer, I got graft versus host disease, which made me very sick – it felt like I died a few times. Fortunately, after a lot of research, they were able to cure me from that. So, that also confirmed that waiting for that so-called ‘magical’ five year mark before contacting the donor, was a good decision.

“I did not have any control over my own body. I felt desperate and powerless.”

That must have been real hard, to get so sick after healing from cancer…
I did not have any control over my own body. It mainly affected my gut and later on also my skin.  I felt desperate and powerless. I was extremely dehydrated, and I had random blackouts that I did not even consciously experience. It was horrible. Fortunately, I fully recovered and can now enjoy the outdoors, biking and walking again.

To conclude, what would you like to say to people who are considering to become a stem cell donor, or who are still hesitating?
The beauty of this day and age, is that most of stem cell donations are taken via blood. In only a small proportion of donations, stem cells are taken from bone marrow. Most people can donate via blood, which involves growth factor drug injections, followed by harvesting by means of the apheresis machine. This procedure typically comes with mild, flu-like side effects that last only a couple of days. Then it is gone. So, if you are willing to pay that relatively small price, to really make a difference for a patient in need of a stem cell transplant, please… do not miss out on that opportunity! There are so many people who deserve it, just as I was lucky enough to receive stem cells from that young woman in the US. To all young men and women: let’s go, come on, please, join the registry!

——-

We thank Frans for taking the time to meet with us, and hope that you are as impressed with his story as we are. If you want to read Frans’ full story, you can go to his website: www.franspaymans.nl.

Are you inspired to become a stem cell donor and give someone a chance to live? Go to www.GenDx.com/stem-cell-donation/ to learn more about how you can register.

 

 

 

 

Meet GenDx at ASHI 2021

We are happy to announce that GenDx is supporting ASHI 2021 with a corporate sponsorship! The conference will be held this year from Monday, September 27 to Friday, October 1 and the participants will have the opportunity to attend physically or virtually.
Make sure to join us in our activities!

Teaching Session – FULLY BOOKED

September 27, 2021 9:00 am – 02:30 pm (EDT, Orlando time)

This year, we will hold this event virtually. The session will focus mostly on HLA typing by NGS.

More information and complete program here

Tulip Run

September 29, 6:00 am – 7:30 am (EDT, Orlando time zone)

Walk or run to this event, organized by GenDx, and join us on the common goal: enhancing the outcome of transplantation. The 5K Tulip Run will begin at 6:30am at the Hyatt Regency Grand Cypress.

Find photos from previous Tulip Run events here

User Group Meeting

September 30, 01:00 pm – 02:00 pm (EDT, Orlando time)
Speakers:

  • Pascal van der Weele PhD, Project Manager R&D at GenDx will talk about our latest development on Chimerism monitoring by NGS based on indels rather than SNPs and the accompanying software package: TRKengine.
  • Hanneke Merkens PhD, Associate Director Education at GenDx, will share exciting preliminary results of our platform comparison study where long read data from Pacbio and MinION are compared to short-read data; is long read sequencing becoming the new golden standard for HLA?
  • Maarten Penning PhD, Chief Technology Officer at GenDx will give an update on our newest multiplex strategy NGSgo-MX11-3; giving the highest possible quality data and highest possible ambiguity resolving power.

More information and the complete program of the UGM here

Virtual booth

September 27 – October 1, 09:00 am – 05:00 pm (EDT, Orlando time)

Stop by and say hi to your favorite representatives on our Virtual Booth!

Posters 

Our posters will be available online on the ASHI platform as well as on our online Virtual Booth.

  • NGStrack® performance and informativity analysis of 154 samples (Pascal van der Weele et al)
  • A multiplex whole gene HLA typing strategy evaluation on various platforms:
    both long reads (PacBio, ONT), and short reads (Illumina, Ion Torrent) (Diya Gao et al)

 

Looking forward to (e-) meeting you!
For more information and registration at ASHI, visit https://www.ashi-hla.org/

Release NGSengine 2.22.0

NGSengine has been updated!

We have released the new version of our NGSengine software. Version 2.22.0 includes several new features and improvements, and the latest IMGT/HLA database 3.44.1.

Some important new features

  • Analysis of NGSgo®-MX6-1 and long-read alignment have been significantly improved.
  • IMGT/HLA database 3.44.1 is included and selected by default.
  • Improved the security of user credentials.
  • All unpublished splice sites are extrapolated with the common nucleotides, which was not the case for DPB1, DPB2 and HLA-H. This will allow easier identification of new splice site variants and putative null alleles.
  • At the locus analysis preferences, the “Set all loci like HLA-A” button is changed into a “Set all locus like selected locus” button.
  • The name of the saved PDF report is automatically based on the scope (project/ group/ sample/ locus).

Update now!

Make sure to update your software to the latest version to have access to the new features and the latest database. For a complete overview of all new updates, please check the release certificate.

Download Software update

Download Release certificate

Tulip Run donation to Beatson Cancer Charity

£2.029 cheque handed to Beachon Cancer Charity

Thanks to the contributions of the participants of the #EFI2021 virtual Tulip Run and the multiplication from GenDx, EFI president Ann-Margaret Little and her colleague Helen McFarlane were able to hand over a cheque of £2.029 to the Beatson Cancer Charity in Glasgow. COVID restrictions caused a delay in the in-person handover, but happily, it could be realized now.

Grateful thanks to everyone who contributed!

Maisie McCormick, Community Fundraising Manager at Beatson Cancer Charity mentioned: “On behalf of everyone at Beatson Cancer Charity, thank you for your kind and generous donation of £2,096.79 raised through this year’s Tulip Run. What an incredible donation – it just goes to show how your generous clients and contacts used their initiative and got out to do their run wherever they were, despite not being with others. We are thrilled at having received such a fantastic donation. Please pass on our grateful thanks to everyone who contributed in some way. Thanks to your support we can continue to invest in services, staff, research, and education to provide a better future for those affected by cancer”. 

 

Thank you all for your support and looking forward to meeting you at the next Tulip Run event!

 

 

 

NGSgo®-MX11-3 registered as CE-marked IVD

GenDx has registered NGSgo®-MX11-3 as CE-marked IVD

The product can now be used for accurate HLA typing of donors and patients in need of organ or stem cell transplantation. The approval of NGSgo-MX11-3 completes the series of our CE-marked IVD amplification products, including a singleplex (NGSgo®-AmpX v2) and a six-gene multiplex (NGSgo®-MX6-1) strategy for HLA typing by Next-Generation Sequencing (NGS). All amplification products can be used in combination with the recently CE-marked IVD Library Full Kit for indexing, library preparation, and cleanup.

NGSgo-MX11-3
NGSgo-MX11-3 consists of amplification primers for eleven HLA genes (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, DRB3/4/5, DQA1, and DPA1). The three-tube design results in low noise levels and well-balanced alleles, providing similar high-quality data with the 11-loci multiplex compared to the singleplex strategy.

Dr. Wietse Mulder, CEO of GenDx, commented: “We are proud to now offer the NGSgo-MX11-3 multiplex amplification for diagnostic use, and we are convinced this innovative product will accelerate the demand for high-quality multiplex data for stem cell transplantation

Read the complete press release here

HistoTrac now fully compatible with NGSengine

Starting from NGSengine version 2.20, the software reports the Bw4/6 status of HLA-B alleles (based on the ALLAN tool*) in the overview, genotype ranking, TARR export, and the PDF report.

We are happy to announce that HistoTrac now accepts the tarr file as input and thus labs are able to transfer the Bw4/6 assignments directly into NGSengine.  In addition, making use of the conclusive typing feature is now compatible with the import as well as the transfer of NMDP codes, if there are ambiguous typings.

 

Interested?

Contact HistoTrac today to have your module updated so you can make use of this feature.

 

*Kaur N, Kransdorf EP, Pando MJ, Maiers M, Ray B, Lee J-H, Lalli P, Murphey CL, Bray RA, Gragert L. Mapping molecular HLA typing data to UNOS equivalents. Human Immunology. 2018: doi.or/10.1016/j.humimm.2018.08.002

 

BLOG: Together to the Top: the first training

In this blog, we follow the journey of our colleagues Stefan Timmerman and Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. They will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk and Stefan are the lucky GenDx representatives to support the Give&Live cycling club on their way to the top of the mountain. 

June 5, 2021

Today, Saturday June 5, we have the first training event of this year ,taking place at the Holterberg. The group of participants gathered at 09:30 am, ready for a day of cycling and socializing! It was perfect day for cycling; cloudy, nice temperature and dry weather. But before we started, time for a cup of coffee and a lunch.
After an introduction of all participants (approximately 30 in total), it was clear that meeting and supporting each other was the most important goal of today. The group was very diverse; there were organ- and stem cell recipients, donors, medical staff from UMCG and even family members of people who passed away due to the unavailability of a donor. You can imagine that the stories of family, friends and the people who have received an organ were impressive to hear. They all seem to value life more consciously, while at the same time they are extremely aware of the vulnerability of their health.

Around 10:30 am it was time to start cycling! Some people who have received a new organ turned out to be extremely good at cycling, while others had the feeling that they have to learn cycling all over again. That is where we, Henk and Stefan, come in. As cycling buddy, it will be our task to support those who have difficulties climbing the mountain. This will be a humble task for us to accomplish.

The training ended at 3:00 pm. On our way back home, we both concluded that it was a great experience to meet everybody and listen to their personal stories.  Through this experience we realized more than ever why we are doing our utmost best to provide our customers with the best products and software: to ultimately improve the life and survival rate of transplant patients.

Henk & Stefan

 

Interview with three-time leukemia survivor Tom Barendregt

For those who have faced a deadly disease such as leukemia, it seems like life has been divided into ‘before’ and ‘after’. When you are on the waiting list for a stem cell transplant, you just have to wait and hope a suitable donor will be found. We got to interview leukemia survivor Tom Barendregt (22) about successfully battling this violent disease not once, not twice, but three times. Read more about Tom’s first-hand experience in receiving a stem cell transplantation and his understanding of how crucial it is to have strong spirit during such uncertain times.

Can you tell me a little bit about yourself. What is your life like and how did you get diagnosed with leukemia for the first time?
Before I got diagnosed with leukemia, I played ice hockey on a professional level. On the age of fourteen I already got my first professional contract in the first division of the Netherlands. When I was fifteen, I transferred to the Colorado Thunderbirds in Denver in the United States. I played here for one year, but due to compulsory education, I had to move back to the Netherlands to finish school. While finishing school I played in the Dutch first division again. From the moment I finished school I moved back to the US to play in the USHL, the highest league in the world for guys until the age of 21. Just before the start of the season I started to get weird symptoms like extreme tiredness, bruises on my body and pain in my lower back. I visited multiple doctors and tried different therapies, but nothing seemed to help. I decided to go to the hospital where they took a blood sample. They immediately diagnosed me with leukemia, a disease I had never heard about before. My suggestion was to give me some medication so that I could start the ice hockey season. But when they told me that the leukemia was in a very far stage and that one ice hockey puck to my body could be life threatening, I realized that it was very serious. Instead of starting the ice hockey season, I ended up in the hospital to start chemotherapy. The start of another type of top sport: fighting leukemia.

“I ended up in the hospital to start chemotherapy. The start of another type of top sport: fighting leukemia.”

So when you got diagnosed with leukemia, you were all alone in a foreign country?
Yes, that’s right. The only people that were around at that moment were my host family and my former girlfriend, who was about to start her study in Madison. Since the leukemia was already in a very far stage, it was too risky to fly me back to the Netherlands for treatment. One day after the diagnosis, I was hospitalized in the University Hospital in Madison and my father and the father of my former girlfriend travelled to the US to support me in the process.

Can you tell us something about what you have been going through from the moment you started treatment?
Before I started treatment, I was confronted with the message that the treatment would pose a high risk for infertility. I was 17 years old at that time, so I wasn’t thinking of having children at all. However, to be prepared for a potential wish for children in the future, I was sent into a room with a plastic jar and a playboy magazine. Then we started the induction phase, which is 30 days of chemotherapy. After one week I got a severe allergic reaction that nearly killed me. For the remaining 3-4 weeks they switched to intramuscular chemotherapy, which is given as injection into a muscle. I had many bone marrow punctures and lumbar punctures to see if there was cancer in my brain. Luckily there were no cancer cells in my brain, but they injected chemo there anyway for preventive reasons. After all, leukemia can hide anywhere.

“Leukemia can hide anywhere”

How long did it take until a suitable donor was found and you actually got a transplant?
There are multiple ways to fight leukemia, a stem cell transplantation is not always part of it. In my case, they decided on a treatment without a stem cell transplantation at first, so only chemotherapy and steroids. Four months after my diagnosis, they recognized that my leukemia was pretty aggressive and they therefore decided to change the method and continue with a stem cell transplantation. I consider myself lucky that I quickly matched with multiple donors in the database. When you are more racially mixed, it gets more complicated to find a donor and it often takes months or even years. Time you don’t have when you suffer from a life threatening disease like leukemia. Before you start with the stem cell transplantation, you receive treatment to destroy the cancer cells, your own bone marrow cells, and immune cells. So your body is quite destroyed. Then you get a transplant.

“I consider myself lucky that I quickly matched with multiple donors in the database”

How long did the recovery take place
From the moment you receive the stem cells, you are far from done. First of all you are monitored regularly to measure the effectiveness of the transplantation. In my case, I had pretty severe graft-versus-host symptoms, meaning that the donor T cells were attacking my healthy cells.
After approximately 9 days, they saw that it was starting to work. Exactly two weeks after I got my transplant I left the hospital. This was extremely fast, because normally you’re there for 6-8 weeks. After 3 months they did a bone marrow puncture to check how much of the bone marrow was now from the donor.
The whole transplantation and coping with its side effects took me an additional 7-9 months. And like I said, even when they don’t see the leukemia anymore, it can always come back.

And it did come back… twice.
How did the second and third treatment compare to what you had been through already? Did it start all over again, or was it different from the first time?
With my second diagnosis they suggested a new treatment method called CAR-T therapy. In CAR-T, T-cells are taken from your blood and modified in the lab by adding a man-made receptor. This receptor helps to identify the bad cells.
The third treatment was comparable with my first since I had a stem cell transplantation. In principle these treatments were pretty much the same, the main difference was that with the third treatment they used immunotherapy instead of chemotherapy. Immunotherapy is a relatively new cancer treatment that boosts the immune response in the body as well as teach the immune system how to identify and destroy cancer. The reason why they tried this different method is because there were mutated leukemic cells hiding in my testicle. Since these mutated cells had another genetic code (CD22), it was not recognized by the CD19 CAR-T cells.
An interesting fact is that both with the second and third diagnosis, the leukemic cells were hiding in my testicles. More and more research shows that this is a very common place for the cells to hide in a men’s body, therefore radiation on the testicles is included in the standard treatment procedure in the US. Upon my last treatment, I had twelve radiation sessions on my testicles just before the transplantation. This was to minimize the chance that leukemic cells were able to hide there again.

Your third fight against leukemia was during the first months of COVID-19. Since your immune system was (about to be) killed by chemo, were you afraid that COVID-19 could get to you? |
When you are in the process of radiation and stem cell transplantation, a cold is already dangerous to you. So you are very careful, whether there is a pandemic or not. At that time, the lockdown was in effect and the only main difference I experienced was that the visitor schedule in the hospital was heavily regulated. I therefore took a flat screen TV with PlayStation and some dumbbells with me to the hospital to keep myself busy. After the transplantation it was easier to go outside, since it was very quiet on the streets and everyone kept their distance.
Since acute leukemia is life-threatening, unlike other less life-threatening diseases, they didn’t postpone my treatment and transplantation. Because of the pandemic, it did take a bit longer to transport the stem cells from my donor in Germany to the Netherlands.

You have beaten leukemia three times now. After so many times, how do you stay positive?
I think the most important thing is that I put everything in perspective. When I think of everything I have been through and the fact that I nearly faced death, every day that I am not ill is a good day. Nowadays, I only put effort in the things I like to do and invest in the persons I like to have around me. I enjoy life to the fullest. By eating a healthy diet and exercising regularly, I make sure my body is ready for any battle to come.

“I focused on the things I could control, and let go of what I couldn’t”

What would you say to someone who is  at the start of the fight against leukemia or another type of cancer?
It is hard to accept that you don’t have control over the way your body is dealing with the disease and whether your will survive or not. What helped me a lot was to focus on the things I could control, and let go of what I couldn’t control. For me this meant that good nutrition and exercise was more important than ever and I focused on gaining knowledge about the disease so that I could join the conversation and be involved in the decision-making process. Being in control over the things you can control also gives you peace. In case you would die, you would at least know that you did everything within your power.
Another thing that I would recommend is to focus on the people that you really care about. When you are diagnosed with leukemia or any other life-threatening disease, you get a lot of attention most of the time. Instead of investing in all these people, focus on the ones you rely on and care about the most.
It might also help to get in touch with fellow sufferers since they truly understand what you are going through.

Last question: were you able to play ice hockey on a professional level again?
The thing is that you have a higher chance on playing ice hockey on a professional level when you perform well in a junior hockey league between the age of 18-21. I was treated for leukemia at that time, therefore I have a slighter chance to get a contract in the US. Playing ice hockey in the first division of the Netherlands might be a possibility, however this is not the level I used to play so then it would be more like a hobby.
Therefore, I am focusing on other things at the moment. I get a lot of energy from motivational speaking and being an entrepreneur, working on healthy food products in cooperation with an American company. I just enjoy life to the fullest and focus on the things that make me happy!

Thank you Tom, for the inspirational story! It is really admirable how positive you are. We wish you all the best for the future!

Do you want to learn more about stem cell donation and how you can join the registry?
Click here for more information and registration.

NGS Workshop – How to implement NGS HLA typing

GenDx is hosting a workshop on NGS HLA typing on June 16, 2021 (9:30-12:30 CDT, Chicago).

Registration is free of charge and open to everyone. We will give you insights about the advantages of implementing HLA typing by Next Generation Sequencing for transplantation purposes. You will learn what it means for your own lab, in terms of lab workflow, equipment, and training to switch to next-generation sequencing.

Presentations will be given by the GenDx team, and we are delighted to welcome Dr. Olga Timofeeva from the HLA lab at MedStar Georgetown University Hospital as a guest speaker. She will share their story of successfully implementing the HLA typing by NGS in their lab. This workshop will be an online interactive meeting using the GoTo meeting application.

For more information regarding the workshop, feel free to contact us.

GenDx at ASHI Regional Education Workshop

ASHI Regional Education Workshop will take place fully virtually on Friday June 4 and Friday, June 11, 2021. Will you attend the workshop as well?

Innovative Technology Talk
Join our Innovative Tech Talk on June 4, 2021 at 4:15 pm (EDT) to be updated about our Multiplex product for HLA Typing: NGSgo MX11-3 and our Chimerism by NGS products: NGStrack® and TRKengine®. Andrea Zimmerman MSc, Associate Director Sales & Education North America, is happy to answer any questions you might have in the subsequent live Q&A.

Say ‘HI’ to your favorite Application Specialists!
Meet our Application Specialists at the ASHI Regional Education Workshop! You can join them in our virtual meeting room at any time during the workshop or send a chat message to get in touch. We look forward to e-meeting you!

Start a meeting!


Explore our booth
Our 3D booth is ready to be explored by you!

  • Check our product presentations
  • Find online brochures
  • Explore NGSengine by video
  • Educate yourself by our  prerecorded webinars
  • Join our quiz & win!
  • Chat with our application specialists

Access our booth via the  e-Conference platform or directly via meet.gendx.com

Let’s connect at the ASHI Regionals. See you there!

GenDx at EFI 2021

The virtual event took place from April 21 to 23. We were very happy to see that many of you got in contact with us or with our distributors in our virtual booth, showing a lot of interest in our products, thank you for that! Some of our materials from the event are now available online and can be found in the links below so feel free to check them out!

The posters that were presented are now published on our website. Make sure to check them out and get updated with our latest developments.

GenDx posters at EFI 2021

The topic of this year’s Satellite symposium at the EFI virtual event was Improving transplantation success by NGS-based chimerism monitoring & genotyping beyond classical HLA genes. For those who have missed it, you can now watch the video following the link below

Satellite Symposium EFI 2021

Last but now least, did you participate in the virtual edition of the Tulip Run? If you did and shared a picture with us, you can find it highlighted on our website at the Tulip Run gallery. On the Tulip Run gallery, we share the photos and videos of completed Tulip Runs all over the world.

Until next year at the EFI 2022 in Amsterdam!

EFI Satellite Symposium: Excellence in sharing – watch the recording

The topic of this year’s Satellite symposium at the EFI virtual event was Improving transplantation success by NGS-based chimerism monitoring & genotyping beyond classical HLA genes. Many of you watched the prerecorded session and showed a lot of interest in our topics, thank you for that!

For those who have missed it, you can now watch the video here:

 

Program of Satellite symposium – Excellence in sharing:

  • The role of MICA  and MICB in transplantation – Seiamak Bahram MD PhD, Professor of Medicine (Immunology)
  • Clinical relevance of molecular markers in hemato-oncology – Lisette van de Corput PhD, Medical Immunologist at UMC Utrecht
  • Chimerism monitoring by NGS: NGStrack & TKRengine – Pascal van der Weele PhD, Project Manager at GenDx
  • New developments – Maarten Penning PhD, CTO GenDx

Chaired by Wietse Mulder PhD, CEO at GenDx

 

If you have any questions, feel free to reach us at marketing@gendx.com.

BLOG: Discover our DNA

Discover the DNA of… Hannah Monsuur

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. Our team consists of specialists, strategists, technicians, developers and creatives, all with different competences but with the same drive: to improve the quality of life of transplant patients worldwide. In our blog Discover our DNA, we like to introduce you to the people behind GenDx. This time we are happy to introduce our colleague:  Hannah Monsuur

Hannah in a few words
Caring, creative, friendly, good-humored

What position do you fulfill?
Technical Support & Education specialist
I help our customers by answering their technical questions, ranging from troubleshooting laboratory practices to NGS data analysis. Together with the rest of the technical support team I am also responsible for communicating customer needs within the organization. A big part of my work is providing education, either by providing extensive answers to support questions or by actively reaching out through webinars and training courses.

What motivates you in your work?
When you put in a lot of effort writing down an educational answer to a customer’s question and then receive their feedback which shows they grasped the concept, that is really satisfying.

What achievement are you most proud of (work related)?
Our biggest challenge last year was to get everything going despite the pandemic. Normally we host training events at our office and at the EFI/ASHI conferences. Due to COVID-19, these had to be replaced by online alternatives so we could keep training our customers and sharing our knowledge. We started this new challenge by hosting a series of webinars to replace the teaching session of the cancelled EFI conference. We increased the frequency of the webinars and then noticed that more and more people were joining  on a regular basis. The training courses, which normally included training in the lab, were replaced by online training events with videos to demonstrate the workflow in the lab. We have also been working on new training materials. I am proud of the Support and the Education team for being able to improve our services over the past year, despite the pandemic. When it is possible we would of course like to see everyone in real life again!

What is your passion, besides your work at GenDx?
Outside of work I enjoy going to the zoo with my niece or nephew, spending time in the garden watching my rabbits make funny jumps, going to a museum, having drinks with people; basically all kinds of activities with my family, friends and colleagues. Another thing I love to do is travelling. I have many good memories of faraway travels, but the past year I have also really enjoyed exploring our own little country, there is still so much to see!

What do people probably don’t know about you?
Since my work and also my personality cause me to be ‘inside my head’ a lot of the time, I like to counteract that. Over the years I have participated in painting classes, figure drawing classes, a French language course and pottery classes. Also swimming, cycling and practicing yoga keep me from thinking too much and bring me in the here and now.

BLOG: Together to the Top: the introduction

In this blog, we follow the journey of our colleagues Stefan Timmerman and Henk van Laar, to reach the summit of the Mont Ventoux in June 2022. They will be joining the Give&Live cycling club, which is a group of cyclists that are either organ- or stem cell recipient, donor, or working in the field of transplantation. GenDx sponsors the event, and Henk and Stefan are the lucky GenDx representatives to support the Give&Live cycling club on their way to the top of the mountain. 

We are honored that our colleagues Henk van Laar and Stefan Timmerman have the opportunity to climb the Mont Ventoux together with a group of fit transplant patients and donors. Let’s shortly introduce Stefan and Henk to you:

Stefan Timmerman
My name is Stefan Timmerman, 36 years old, and I am working at GenDx as CFO for two years now. I live in Zeist with my girlfriend and daughter of 2 years old. In my spare time I often make long distance tours on my racing bike or I go for a mountain bike trip in the woods. In the past two years I have learned a lot about transplantation, especially about transplantation diagnostics. At GenDx, our goal is to help transplant patients worldwide. By participating in the Give&Live cycling event, I want to better understand the stories of both transplant patients and donors.

Henk van Laar
I am Henk van Laar, 60 years old, married to Anna, have 2 daughters and I live in De Meern. I have been working at GenDx for two years as a Logistics Associate. In this position, I make sure that our reagents are delivered on time anywhere in the world.
As an endurance athlete I have already walked and cycled a lot: from the seabed of the Flevopolders, over the Utrecht Heuvelrug, to the hills of Burgundy. This year I will be training for the Mont Ventoux with my racing bike. What a beautiful (physical and mental) challenge to conquer the Mont Ventoux together with a group of fit transplants and donors!

More information about the Give&Live Cycling Club: https://giveandlive.nl/ 

Collaboration GenDx and University Museum Utrecht

This week a collaboration agreement was signed between GenDx and the University Museum Utrecht (UMU). The financial contribution of GenDx will be used to realize the redesign of the museum.

— Persbericht ————————————————————————————-

Samenwerking GenDx en Universiteitsmuseum Utrecht

Het Universiteitsmuseum Utrecht (UMU) vormt sinds jaar en dag dé plek waar samenleving
en wetenschap elkaar ontmoeten. En met succes: de bezoekcijfers zijn de afgelopen jaren
flink gestegen, van 20.000 in 1996 naar 75.000 in 2019. Daar is het museumgebouw niet op
berekend. Na een grondige verbouwing is er bij heropening voldoende ruimte voor 100.000
bezoekers per jaar. Het UMU ontwikkelt zich van een wetenschapsmuseum tot een echt
onderzoeksmuseum. Volgens het principe van onderzoekend leren nemen we onze
bezoekers actief mee in het proces van wetenschap en laten ze deelnemen aan echt
onderzoek. Dankzij de steun van de Universiteit Utrecht kunnen we het museumgebouw
ingrijpend aanpassen.

Het herinrichten van het museum en het ontwikkelen van nieuwe presentaties doen we in
samenwerking met partners die het belang van onderzoek en wetenschapswijsheid
onderschrijven. De komende jaren zal GenDx, specialist in DNA-diagnostiek voor het
genetisch matchen van transplantatiepatiënten met donoren, een belangrijke financiële
bijdrage leveren aan deze herinrichting.

Wietse Mulder, CEO van GenDx: “de samenwerking met het UMU past ons goed. Wij weten
wat het betekent om als donor het verschil te maken. Het is daarom onze missie om de
kwaliteit van leven van transplantatiepatiënten wereldwijd te verbeteren. Dat vraagt veel
onderzoek. We vinden het essentieel dat het belang van onderzoek en wetenschap zichtbaar
is voor een breed publiek. Het UMU laat dat op innemende manier zien”.

“We zijn erg blij met de bijdrage van GenDx. Het brengt ons weer een stap dichterbij de
realisatie van onze droom”, aldus Paul Voogt, directeur van het UMU.

GenDx at EFI 2021

EFI 2021 will take place fully virtually from Wednesday, April 21 to Friday, April 23 and we are proud to be one of the Gold Sponsors. Make sure to visit our virtual booth and attend our activities in the comfort of your own home or office. You can find the detailed program with all activities here.

Virtual booth
Here, you can check our latest posters and product presentations, find online brochures, explore NGSengine by video, educate yourself by our prerecorded webinars, and chat with our application specialists and distributors.

Satellite Symposium
Don’t forget to participate in this year’s edition! You can watch the prerecorded session on demand. The topic is Improving transplantation success by NGS-based chimerism monitoring & genotyping beyond classical HLA genes. If you have any questions, you can reach us via the chat or meeting corner in our booth.

Tulip Run
Last but not least, participate in the virtual edition of the Tulip Run. Find your own perfect 5 km running route in your city and run it during one of the EFI conference days. Register now and don’t forget to share your picture with us!

We look forward to e-meeting you!

Tulip Run EFI 2021

No in-person EFI conference in the vibrant Scottish city of Glasgow, but a virtual edition. Since it became a tradition at EFI conferences to organize a Tulip Run, we challenge you to do a 5 km run in your own city during one of the EFI conference days. On this page, we share the photos and videos of completed Tulip Runs all over the world:

GenDx medewerkers in beweging voor het Prinses Máxima Centrum en Stichting Leergeld Utrecht

UTRECHT – Van 2 maart tot 22 maart heeft GenDx, een bedrijf in de moleculaire transplantatiediagnostiek, haar medewerkers uitgedaagd om in beweging te komen voor het Prinses Máxima Centrum en Stichting Leergeld Utrecht. Ruim voor de deadline was het maximaal te behalen bedrag van €5.050 al verzameld door circa 40 sportieve medewerkers. Op woensdag 31 maart jl. zijn de cheques van 2.525,-  per doel overhandigd.

De doelstelling van GenDx Charity Challenge is bijdragen aan de fysieke en mentale gezondheid van medewerkers van GenDx in een periode waar – gedeeltelijk – thuiswerken, sluiting van sportscholen en -verenigingen, en minder sociale contacten het leven beïnvloeden. Deze activiteit sluit perfect aan bij de waarde van GenDx om te delen, hetgeen we ook binnen het werkveld van transplantatie diagnostiek van groot belang achten.

GenDx, gelegen op het Utrecht Science Park, is als spin-off van UMC Utrecht een van origine Utrechtse onderneming.  Wij zijn trots op ‘onze afkomst’ en steunen daarom verschillende lokale organisaties, waaronder Stadsschouwburg Utrecht, sportverenigingen Histos, Triton, Orca en SPIN en zeer recent het Universiteitsmuseum Utrecht. Voorafgaand aan de start van GenDx Charity Challenge kregen onze medewerkers de kans om een goed doel te kiezen uit een lijst van zowel lokale als internationale initiatieven, met als resultaat de keuze voor het Prinses Máxima Centrum en Stichting Leergeld Utrecht.

Beide organisaties willen het gedoneerde bedrag gebruiken om kinderen te laten bewegen. Stichting Leergeld Utrecht zet het bedrag in voor een specifiek project om kinderen uit lage-inkomens gezinnen te ondersteunen met hun contributie voor sportclubs. Binnen het Prinses Máxima Centrum wordt de donatie gebruikt voor de afdeling Quality of Life. Hieronder valt ook het Maximaal Bewegen project, dit programma richt zich op een sneller en beter herstel van kinderen met kanker door voldoende beweging en een verlaging van de stress bij kinderen en ouders tijdens het behandelproces door afleiding en sporten.


Overhandiging cheques op woensdag 31 maart 2021. Foto boven: Roelien Brommersma (GenDx) en Harmen van de Kamp (Stichting Leergeld Utrecht), Foto onder: Nienke Beek (Prinses Máxima Centrum) en Manon de Jong (GenDx)

Download Persbericht

BLOG: Discover our DNA

Discover the DNA of…  Marcin Braams

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. Our team consists of specialists, strategists, technicians, developers and creatives, all with different competences but with the same drive: to improve the quality of life of transplant patients worldwide. In this blog, we would to introduce you to the people behind GenDx. This time we are happy to introduce Marcin Braams.   

Marcin in a few words
Reliable, accurate, made for multitasking

What position do you fulfill?
Quality Assurance Associate
As a Quality Assurance Associate I am responsible for the quality of all the GenDx processes. In this position, I am continuously looking for improvements in our processes.

What motivates you in your work?
First of all, I really enjoy the work atmosphere at GenDx, the open door policy really makes it easy to interact with colleagues from different teams. This results in great teamwork within the company. I’m working with a diverse set of colleagues and each successfully completed project is a great motivation. A project is always a team effort and it gives a great feeling of satisfaction when the project leads to improved processes. Another thing that really motivates me is the variety of projects I am working on. Some projects are relatively small and completed easily in a short amount of time, while some projects can be really challenging and take months, or even years.

What achievement are you most proud of (work related)?
I started working at GenDx as a technician. During my time as technician, I had to make some choices which lead to the start up as my function as a Quality Assurance Associate (QAA). As QAA I’m involved in lots of processes which need to be improved, and I’m also co-responsible for certain processes. I’m really proud that I made that challenging choice at the time because it enabled me to work with lots of different people and new challenging projects.
I’m also proud of the people I’m working with. Most of the projects require “out of the box” thinking, a different mindset and a bird’s-eye view in order to uphold quality, implement improvements, and come up with new ideas.

What is your passion, besides your work at GenDx?
I really enjoy doing sports. I’m currently part of a triathlon organization and I’m also regulatory running with my brother or friends. I specifically like water-related sports like swimming, rowing or surfing.

What do people probably don’t know about you?
I have a strange habit of accepting challenges from my friends or challenge myself. This led to funny and strange events like running half a marathon on the beach, and getting a license to operate small boats or follow kite surf lessons from sunrise to sunset. My latest challenge, set by myself, is learning a fourth language on B1 level in order to communicate with friends who moved to foreign countries.

Run with us during EFI 2021!

In a few weeks, the EFI conference will start. Unfortunately no in-person event in the vibrant Scottish city of Glasgow, but online attendance in the comfort of your own home or office.
Since it became a tradition at EFI conferences, we can not let the conference pass without the Tulip Run. Therefore we invite you to participate in a virtual edition of the Tulip Run!

How?
In Glasgow, we planned a beautiful running route starting at the conference venue, along the Clyde River to the Riverside Museum and back. With a distance of 5 km, the perfect run to start the second conference day. Curious about the Glasgow route? Watch the video and virtually explore the route including all highlights:

With this in mind, we like to challenge you to find your own perfect 5 km running route in your city and run it during one of the EFI conference days. Of course you can’t run without a proper running shirt, all participants therefore receive a Tulip Running shirt at their home- or office address.

Ready to run with us? Register now!

GenDx’ HLA typing products IVD registered at Health Canada

We are proud to share that we have completed IVD registration in Canada for our HLA typing products NGSgo®-AmpX v2 and NGSgo®-MX6-1.

Our CEO Wietse Mulder commented: “We have worked intensely to validate and document these NGSgo products according to the Health Canada IVD regulation. It took a great deal of work to complete, and we are proud to be the first supplier that can offer this IVD product for the transplant community in Canada. We believe the products will truly support better typing of the HLA genes.”

Press release GenDx IVD registration Health Canada

GenDx proud sponsor of Transplantoux

Our mission is to improve the quality of life and survival of transplant patients worldwide. With a team of over 60 passionate employees, we are committed to develop innovative products and actively support charities and institutions that share our mission.
It is therefore with pride that we support the Transplantoux event of the Give & Live Cycling Club. We are honored that our colleagues Henk van Laar and Stefan Timmerman have the opportunity to climb the Mont Ventoux together with a group of fit transplant patients and donors.

More information about the Transplantoux and Give&Live Cycling Club: https://giveandlive.nl/ 

BLOG: A day at Support

I am Hannah Monsuur and I am Technical Support Specialist at GenDx. Our Support team consists of 5 persons: Veerle van Meervelt PhD, Zhen Ping PhD, Elja Louer PhD, Yvonne Dorland PhD and myself, Hannah Monsuur PhD. At GenDx, we have a strong focus on excellent customer support and strive to answer every email within 24-hours.  On a yearly basis, we assist customers from 55+ countries around the world with product questions, practical matters, data interpretation, and more. In this blog I would like to take you along in a day at GenDx Support.

At 9 am we start the day with our daily scrum, we have quite a lot of e-mails today! Since we are all working from home due to the pandemic, we are meeting each other online. In the scrum we go over each e-mail, if needed we shortly discuss the case and then we allocate the e-mail to one of our team members. We get all kind of questions, you can think of requests to renew a license, questions about Sanger, a new lab asking for help with the NGS workflow, challenging NGS data analysis questions, etc.

Yesterday we received a particular challenging case, the customer sent us NGS data which they could not interpret. It is potentially a novel allele, but it might also be a sequence artefact. Elja has been working on this question, but since it is so challenging we decide in the scrum that Veerle and Elja will further discuss the case together. Two people always know more than one!

” Two people always know more than one! “

At 10 am, Hannah has a meeting with a customer who will perform their very first NGS workflow. Together with Technical Application Specialist Robert Welleweerd B.ASc, she will guide them through the steps of amplification in an online meeting. Since the camera will be on the work bench the whole time, Robert and Hannah can follow their steps in detail and give advice while the workflow is performed. After lunch an e-mail in the inbox shows us a gel picture with very nice amplicons, the meeting has been a success! Tomorrow we continue the workflow with library preparation.

While Yvonne is writing an e-mail to advice a customer about the right settings to analyze MX11-3, the phone rings! It is a customer from Germany having difficulties while loading the sequencer. It is a difficult question so she quickly discusses the question with a colleague, continues the call with the customer and to the relieve of the customer the issue is resolved. Now back to the MX11-3 question as there are still multiple questions waiting to be answered.

Ping has been helping our distributor in China, they needed help with Sanger data which did not align to the reference. Luckily it was just a matter of giving the .abi files the correct name. Once he finishes the last question allocated to him during the scrum, he takes another look at the inbox and continues with a new question.

” There is never a ‘normal’ day at Support “

It is 5 pm and Elja has finished an elaborate e-mail to the customer explaining why the data was indeed a novel allele. There is also an e-mail from someone we helped last week, she thanks us for the great help with her data analysis question and informs us that we can use her case for one of our NGS case study webinars. Today we have answered many e-mails and tomorrow we will continue with new questions. There is never a ‘normal’ day at Support, it is always a surprise which questions we receive and whether urgent questions or meetings come up during the day.

BLOG: Discover our DNA

Discover the DNA of… Lili Ortega

GenDx is a global leader in molecular diagnostics and develops innovative products for HLA typing and chimerism monitoring. Our team consists of specialists, strategists, technicians, developers and creatives, all with different competences but with the same drive: to advance the field by offering excellent molecular diagnostic tools and sharing knowledge. In our blog Discover our DNA, we like to introduce you to the people behind GenDx. This time we are happy to introduce our colleague: Lili Ortega

Lili In a few words
Reliable, dependable, inquisitive and trustworthy

What position do you fulfill?
Logistics and Administrative Associate
Manage daily office business and Logistics procedures, everything from the start of a purchase order to completion of delivery and invoicing and solving problems in-between!

What motivates you in your work?
Positive attitudes and enthusiasm from myself and others

What achievements are you most proud of?
Jumping in and taking charge of the Chicago office with little guidance. Managing to get past customers to pay very old invoices! Coordinating the office move. Learning more about HLA etc…. to better understand the nature of the business and able to ask the right questions.
I like to also think of myself very determined to be of value and with my actions moving towards understanding as much as I can to continue to be a benefit to GenDx.

What is your passion, besides your work at GenDx?
My family, children and dogs. They keep me on my toes! Love the outdoors from brisk walking, running, biking, tennis, kayaking to theater and traveling. I also volunteer in the community.

What do people probably don’t know about you?
For as much as I am family oriented, I have a very special relationship with each of my children. My oldest son Christian and I share the love of music. So we have been going to music concerts since he was a child, starting out with classic rock band and moved to touch on all genera’s of music until COVID stopped the world. My middle son Nicholas and I share time kayaking, golfing, talking about world politics and our 401K investments. While my youngest and only daughter Alyssa, still in High School, we share the love of theater and travelling, the 2 things we couldn’t do this past year other than talking about how to catch up on the lost time.  One thing most people do not know about me is that as a child I would go to Europe with my grandmother and spend the entire summer in different parts visiting family. As a kid I always thought that was strange that everyone didn’t do that! Also that I was a bartender for a few years after college. The last thing that most do not know about me is my real name. My real first name is Ljiljana. I am Serbian but born in the US, 1st generation American.
This is me…… 🙂

 

Message from the CEO

Happy New Year!
Three words that may sound more relieving than ever before. This year may gradually bring the freedom we were used to before the pandemic affected our lives. The battle against COVID-19 is ongoing, but the approved vaccines provide us a bright spot on the horizon. Time for a new chapter!

Before we close the book, we would like to thank you for your trust and collaboration, especially in an unprecedented year like 2020. We are thankful that in a year in which we were all confronted with challenges, or were affected personally, we still found ways to work together and stay connected.

Going back to normal
2021 is a year for new hope and optimism. We are hopeful that this year will bring back our ‘normal’ lives, while taking into account the lessons learned last year. Online education, remote demonstrations, webinars and digital congress participation have boosted our online presence and contact with you and other customers. Nevertheless, we would love to travel again and visit your lab, give on-site demonstrations and meet each other in person during conferences. In any case, we will continue to deliver you fast and quick service and support.

Improved approaches
This year we anticipate to bring you new developments and products. Next to the continuous improvement of our multiplexed amplification NGS HLA typing products, we are eager to share new products for NGS chimerism monitoring and blood group typing. Our custom lab service will be expanded, offering our extensive HLA knowledge to you for specific or challenging typing projects. And, since we are continuously looking for new business and partnerships, we are expecting more exciting things to happen in 2021.

We are looking forward to increase the number of educational activities, webinars, training courses and demonstrations, for which we are building a professional recording studio. Excellent customer support will remain one of our top priorities, supporting you no matter how difficult the question or challenging the case.

Together with you, we are starting this new year with confidence and great expectations and we are looking forward to continue our close collaboration to advance the field of transplantation.

Sincerely,
Wietse Mulder PhD
CEO

 

Webinar – PIRCHE Epitope Matching in Kidney Transplantation: A Case Study

Have you heard about PIRCHE?

Register now for our webinar on February 16:

PIRCHE Epitope Matching in Kidney Transplantation: A Case Study

PIRCHE® is a new technology for estimating the risk of immune responses after transplantation. It is the first HLA matching algorithm taking into account the indirect pathway of allo-recognition. PIRCHE currently has more than 650 users in 57 countries.

The input of the algorithm is the HLA genotype of a sample. The output of this algorithm is a score (number), to be considered when searching for a donor.

With NGSengine version 2.16 or higher, you can have access to the PIRCHE export feature. GenDx customers can also receive full access to the full range of PIRCHE epitope matching modules through the PIRCHE web platform. You only need to register selecting GenDx as preferred partner.

For more details, visit www.pirche.com

GenDx sponsor of AFDN

GenDx is a proud sponsor of the AFDN (Allele Frequency Net Database) website. AFND is a very useful tool for researchers as they can search population frequencies of several immune genes such as Human Leukocyte Antigens (HLA), Killer-cell Immunoglobulin-like Receptors (KIR), Major histocompatibility complex class I chain-related (MIC) genes, and a number of cytokine gene polymorphisms. It contains information at allele, haplotype and genotype level depending on the polymorphism. Users can now find on the website data from more than 2000 populations on 7 million individuals.

AFND is currently maintained by researchers at Royal Liverpool University Hospital and the University of Liverpool, in collaboration with other international scientific groups.

GenDx holiday closure

As the end of 2020 is approaching, we would like to inform you about our operational dates during the end-of-year holiday period.

GenDx will be closed between December 25, 2020, and January 2, 2021. To get your order placed this year make sure to place it before December 16 (if you are ordering from within Europe) or before December 11 (if you are ordering from US). For the rest of the world, the last ordering day for this year is December 9.

Orders received after these dates will be shipped in the week of January 4 (Europe and US) or in the week of January 11 (rest of world).

For any inquiries or urgent matters please contact our technical support and our specialists will be happy to assist you.

BLOG: Discover our DNA

Discover the DNA of… Karen Mulderij

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. Our team consists of specialists, strategists, technicians, developers and creatives, all with different competences but with the same drive: to improve the quality of life of transplant patients worldwide. In our blog Discover our DNA, we would like to introduce you to the people behind GenDx. This time we are happy to introduce our colleague:  Karen Mulderij

Karen in a few words
Cheerful, reliable, enthusiastic and responsible

What position do you fulfill?
I am a Technician R&D, which I have been for 2 years now.
My main responsibilities are:

  • Production of numerous GenDx reagents .
  • Quality control of reagents using the MiSeq, qPCR or Sanger workflow.
  • Research and development experiments for new products and procedures.
  • Improving existing products and workflows.
  • Maintenance of laboratory equipment.

Our R&D and production activities take place in different laboratories. Therefore, I alternate every 4 to 6 weeks between these laboratories.

What do you like about your job?
I really appreciate the work atmosphere at GenDx. Teamwork is important, and my colleagues are always willing to help me. . I also like the diversity of my tasks and my responsibilities within the company. My favorite workflow is qPCR because I find the theoretical background very interesting.

Another reason why I like my work so much is because with everything we do, we contribute to the best possible match between patient and donor.

What achievement are you most proud of (work related)?
First of all, I am proud that people know where to find me if they need help. It is very satisfying to know that people trust and value the quality of my work.

Secondly, I am proud of what the team has achieved during covid-19. During the pandemic the technicians had to work harder to produce the same amount of products, because the maximum number of technicians in the lab was restricted. Lastly, I am proud of being responsible for validation and contacts for the qPCR for over a year.

What do you do when you are not at work?
I love watching movies. I enjoy almost any genre, except for horror movies, those I don’t like at all. Besides watching movies, I also like to play board games or card games with friends. My favorite games are The Werewolves, Codenames, Pandemic and Hanabi. I especially like the games where you have to work together in order to win (cooperative play).

What I love to do as well is hiking in the forest or mountains. Hiking trails along small creeks, the real ‘hidden’ places’, I enjoy the most.

What do people probably not know about you?
What people may not know is that I have spent a high school year in America as an exchange student, before I went to college. This was the first time I really stepped out of my comfort zone. A few years later, I went abroad for six more months to study in Australia. Since that time I haven’t lived abroad anymore, but I did move three times within the Netherlands. In December, I will move again and hopefully that will remain my home for the coming years.

Prof. Seiamak Bahram appointed as scientific advisor to GenDx

We proudly announce that earlier this year we have appointed Professor Seiamak Bahram as scientific advisor to our company. Professor Bahram has an extensive knowledge of the Major Histocompatibility Complex (MHC) and in particular the MHC Class I chain-related molecules A (MICA) and B (MICB). His scientific advice will provide valuable input to the company regarding relevant immunological targets and the use of diagnostic assays in a hospital setting.

Press Release Appoinment Prof. Seiamak Bahram.

NGSgo® Workflow videos now available!

The NGSgo® Workflow has now been visualized! We have recorded the protocol steps of the NGSgo® Workflow in 9 separate videos.. In these videos, our colleagues Jannetje Kooij B.ASc, Remco Malestein B.ASc and Robert Welleweerd B.ASc show you how to execute each step of the workflow. The videos can be used as an addition, not as a replacement, to the available Instructions for Use.

All videos are now available on our website: www.gendx.com/gendx_education/instructional-videos-ngsgoworkflow/

BLOG: Discover our DNA

Discover the DNA of… Joris Albers.

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. Our team consists of specialists, strategists, technicians, developers and creatives, all with different competences but with the same drive: to improve the quality of life of transplant patients worldwide. In our blog Discover our DNA, we would like to introduce you to the people behind GenDx. This time we are happy to introduce our colleague:  Joris Albers.  

Joris described in a few words
Creative, enthusiastic, restless and stubborn

What position do you fulfill?
I am a Project Manager Software Development. My main responsbilities are:

– Improving our software products, with a focus on NGSengine
– Final code review, making sure internal and external software qualities are maintained
– Writing technical plans
– Teaching software topics
– Deploying releases

What do you like about your job?
First of all the team I’m working in. In contrary to popular belief, software developers spend a lot of time on discussing the features of the software. These discussions can get pretty intense, but always result in the best improvements for the user. I feel very lucky to work in a team where everyone is motivated to do the best they can. Secondly, developing software, and especially the coding aspect, is just so much fun! Solving challenges requires us to be creative on a technical level. There’s is no better feeling than solving a challenge that results in improving the users’ workflow, and ultimately improves the quality of life of a patient!

What achievement are you most proud of? And why?
The major releases of NGSengine. We have worked on it for a long time to implement lots of new features customers have been asking for. It’s a great feeling to release a new version into the world, after months of discussions, planning, screen mockups, code reviews and tests.

Software developing is like a puzzle and a release is like sending in a possible solution to (parts of) the puzzle. After a release, it becomes the question if the customer likes the solution. The puzzle itself is complex because a theoretical idea is sometimes difficult to realize in code. It is a constant battle between what we want to do and what we can do. Overcoming these obstacles and implementing features that users need, makes me proud.

What do you do if you are not at work?
Apart from the usual stuff – I like to read books, play board games with friends, drink specialty beers and nice wines and I take care of over 35 plants in my house. As a side project, I’m currently working on a LED installation together with a group of friends. This project enables me to program a project that’s not as heavily regulated and tested as during my job. The project started 3 years ago and the LED installation is occasionally used at parties hosted by friends, but also at venues within the Netherlands. During one of the heat weaves in 2019, we have spend a week locked in a basement, soldering the different components together. We were ready just in time for the party where the LED installation would be used.

The combination of hardware and software is something that interests me, because you immediately get direct feedback on the code you write. It’s not just manipulating data, its real, it affects the space around you. After spending a lot of time creating it, it is truly mesmerizing to look at thousands of individual lights that create a stunning visual together.

What do people probably don’t know about you?
I’m really into the electronic early hardcore sound from the 90’s. Examples are Ruffneck, Meagashira, Predator and Marc Acardipane. Enzyme X is great too.  Search for “Up & Down” from Marc Acardiplane & New balance. One of the best!  Most of the songs made by these DJ’s were created before I was born. But if I had lived in that time, I’m sure my head would be bald and my wardrobe filled with colorful aussies.

Introducing NGSgo-MX11-3
Easy as one-two-three

The multiplex you have been waiting for!

Amplification primers for eleven loci are multiplexed in three tubes. The three-tube design results in lower noise levels, better-balanced alleles, and higher quality compared to a one-tube approach. This means more reliable typing results.

From DNA to results in only 1,5 days!

Start your amplification on day 1 and have your typing report on day 2 before noon. You can run 16 samples on an Illumina micro flow cell.

 

Read the press release about the new NGSgo-MX11-3, check out the product information page or read our blog, and try out our new multiplex now!

Meet GenDx at the virtual ASHI 2020

We are happy to announce that GenDx is supporting ASHI 2020 with a corporate sponsorship. The conference will be held virtually this year on October 18-21.
Make sure to join us in our activities!

Tulip Run: October 18-21 (at a time and place convenient to you)
Participate in the online Tulip Run organized by GenDx and join us on the common goal: enhancing the outcome of transplantation.

Did you register before October 5 via the regular ASHI registration form? You will then receive your welcome package to arrive at your home or lab address.

GenDx User Group Meeting: October 21, 2:00 pm – 3:00 pm
Speakers:

  • Prof. Frans H.J. Claas, Leiden University Medical Center, Leiden will give a presentation about the acceptable mismatches in transplantation
  • Pascal van der Weele PhD, GenDx, will give an update about the GenDx solutions on NGSchimerism
  • Sake van Wageningen PhD, GenDx, will speak about the new multiplex NGSgo-MX11-3, available by GenDx

Virtual booth: October 19-21, 1:00 pm – 2:00 pm
Stop by and say hi to your favorite representatives in our Virtual Booth on October 19-21, daily from 1:00-2:00 pm.

Poster session: October 20, 5:30 – 6:30 pm
Abstract title: High-resolution HLA typing with NGSgo-MX6-1 and PacBio HiFi sequencing
Poster number:182

Looking forward to e-meeting you!
For more information and registration about the ASHI, visit https://www.ashi-hla.org/

Tulip Run during virtual ASHI 2020

In a few weeks, the ASHI annual meeting will be held virtually. Even though we will not meet each other in person this year, we are happy the ASHI committee decided on a virtual edition so we all stay connected within the HLA field.

We also decided on organizing a Tulip Run which will be held during the ASHI meeting from Sunday, October 18 to Wednesday, October 21. You can do your 5k run (or walk) at a time and place convenient to you. Share your result with us and make a photo in your special edition Tulip Run t-shirt after your run is completed

Are you in? Register until October 5th! 
5 Steps to participate in the online Tulip Run

1) Register before October 5 via the regular ASHI registration form: https://2020.ashi-hla.org/virtual-registration and wait for your welcome package to arrive at your home or lab address.*
2) When you have received the package, use the textile marker to write down your city or country on the front of the T-shirt. A certificate is included to write down your Tulip Run result, name and location
3) Do your Tulip Run (or walk) at a time and place convenient to you.
4) Submit your time and upload your Tulip Run photo via: https://form.jotform.com/202664398397066 . Feel free to additionally share your photo via your social media channel using #tuliprun2020.
5) For every registration, GenDx will donate an additional $25,- to the COVID-19 relief fund.

With this challenge we hope you will be encouraged to stay active and fit, be connected with the HLA family and united by the common goal: to enhance the outcome of transplantation.

Dutch Donor Recruitment Day

On Saturday September 19, it is World Marrow Donor Day. On this day all donors are thanked for their willingness to donate (blood) stem cells for patients in need of a transplant.

At GenDx we are closely involved by the need for more stem cell donors. We therefore have initiated the yearly Dutch Donor Recruitment Day since 2018, to give attention to stem cell donation and actively recruit stem cell donors. We organize this in close cooperation with Matchis, the Dutch foundation that enables patients with leukaemia and other severe blood disorders to receive stem cell transplantation. On this day, both GenDx employees and members of Utrecht student sport associations SPIN, Histos, Orca and Triton are committed to inform and recruit new donors.

This year we will not physically be present on the Utrecht Science Park, but inform and motivate potential stem cell donors via our online channels instead.

Are you between 18-35 years old, healthy and motivated to potentially save lives? Visit www.matchis.nl for more information about stem cell donation, requirements, procedures and registration.

Share your health, become stem cell donor!

BLOG: NGSgo®-MX11-3: The multiplex you have been waiting for.

With the launch of our brand new multiplex HLA amplification product NGSgo-MX11-3, it is time to learn and discover more about this unique product! We have asked our Project Managers R&D Sake van Wageningen and Bram Luiken to highlight why MX11-3 is the product you have been waiting for…

Bram and Sake, you have been working on the development of the new Multiplex product of GenDx, called NGSgo®-MX11-3. At the moment, GenDx already has a multiplex in its portfolio, NGSgo®-MX6-1, why should we choose MX11-3?

MX11-3 is the latest addition to the GenDx HLA typing product line and is designed to be the new ‘flagship’ amplification product. The product incorporates a lot of frequently requested updates to our amplification products, greatly extending coverage, increased ease of use and high data quality.

Sounds like an excellent addition to the product line! If our customers order MX11-3, what will they find in the product kit?

The kit contains three highly optimized multiplex amplification primer-sets, each with their own reconstitution buffer for dissolving the primers the first time the kit goes into use. Primers and their corresponding buffer have the same cap colour for ease-of-use.

Additionally, you will find tubes of water and Longmix, the only reagent needed for amplification outside of the primers.

You are referring to three multiplex amplification primer-sets. You might be aware that other companies have all 11 loci in 1 tube. Why did GenDx choose to work with 11 loci in 3 tubes, what are the advantages?

The use of 3 tubes allows optimal data quality by separating amplicons and amplification primers that are most prone to generation of hybrid reads or pseudogene/dimer artefacts. This greatly reduces the noise levels in data analysis and allows high mappability compared to one tube approaches. The aim was to generate a simple protocol with the highest data quality so your patients end up with the best possible typing result.

You mentioned that the product is easy to use. Why?

NGSgo-MX11-3 amplification mixtures consist of only 3 components in easy to handle volumes, while all 11 genes are amplified using a single cycling program. Immediately after amplification, equal volumes of each mix are used for pooling (1:1:1) followed by a fixed volume input of 2µl into the NGSgo library preparation workflow. This means that you do not have to quantify your amplicons. The product is designed in conjunction with NGSgo library preparation and NGSengine® analysis has been optimized to analyse MX11-3 data.  

What about coverage? Is it correct that MX11-3 has whole-gene coverage?

The NGSgo-MX11-3 has an increased coverage as compared to the traditional amplification strategies. It combines optimized versions of previously available AmpX v2 whole gene amplifications for HLA class I, as well as DRB1, DRB3, DQB1, DQA1 and DPB1. New are whole gene amplifications for DRB5 and DPA1 and improved coverage of DRB4 exon2 and 3 in 1 amplicon.

Thank you very much for these interesting insights in the new products MX11-3. Last but not least we are very eager to know, when can we start using MX11-3?

NGSgo®-MX11-3 is expected to be ready for shipment early October, 2020 (RUO). You can already place your order, contact your local GenDx representative for more information.

 

Wietse Mulder PhD, CEO of GenDx, inaugurates new boat of student rowing club Orca

2020 is a milestone year for both GenDx and student rowing club Orca. While GenDx celebrates its 15th anniversary this year, Orca will reach its 50th anniversary in October, a huge accomplishment for both.

GenDx CEO Wietse Mulder has been a member of Orca from 1983 to 1996, participating in several rowing races with his Orca team ‘Dé clubacht’. Several other Orca teams were competing at the same time, and there was always some rivalry over which team would get to use the best 8+ boat. As Wietse and his team did not always win the boat struggle, they jokingly said that one day they would buy their own boat.

In the milestone year 2020, Wietse decided to buy the boat for Orca, and on Saturday, August 22, Wietse baptized the brand new 8+ Filippi boat in the presence of current Orca members, as well as his former team members. During the ceremony, Wietse elaborated on his reasoning to support the club and referred to two of his main entrepreneurial strategy principles: ‘Dare to share’ and ’Do not always expect a return of investment’.

After the ceremony, pictures were taken of the boat and the (former) Orca members, taking the COVID-19 restrictions into account. The pictures show the beautiful boat with special GenDx graphics, designed by Leon Hulst from WAT Ontwerpers.

GenDx proud sponsor of ASHI Virtual REW

ASHI Regional Education Workshop have gone virtual! As corporate sponsor, GenDx will give an Innovative Technology Talk on Friday August 28 from 3.30 pm – 3.45 pm, followed by a Q&A. Additionally, we will be happy to (virtually) meet you in the Virtual Exhibit Hall on Friday August 21.

Will we meet you there?

Please have a look at the ASHI regionals website for the full virtual program: http://www.ashiregionals.org/ 
You need to register in order to access the program.

 

Join our webinars in September!

The summer is in full swing! While some are enjoying a well-deserved summer break, others have already enjoyed their holiday and are now keeping the office running.
After a short break in July and August, we will start again with the webinars in September. On September 2 we will kick off with the webinar New features of NGSenginefollowed by the webinar Towards defining the immunogenicity of HLA eplets on September 16.

Attend the webinar and receive 0.15 continuing education credits (CECs).

Stay up-to-date on all our educational events by frequently checking our website: GenDx.com/education. If you have any questions, please contact us directly via education@gendx.com

GenDx and Stadsschouwburg strengthen cooperation

Last week, Wietse Mulder PhD (CEO, GenDx) and Joost Kook (Deputy Director, Stadsschouwburg Utrecht) have signed a new contract for three years to confirm mutual engagement and strengthen their cooperation. Three years ago, GenDx became partner of the Stadsschouwburg Foundation. In the new contract GenDx becomes a founder.

Please find the full press release in Dutch below:

 

GenDx en Stadsschouwburg verstevigen samenwerking

Afgelopen week ondertekenden Wietse Mulder (PhD, CEO van GenDx) en Joost Kok (adjunct-directeur Stadsschouwburg Utrecht) een nieuwe overeenkomst voor drie jaar om de wederzijdse betrokkenheid te bevestigen en de samenwerking te verstevigen. Drie jaar geleden trad GenDx toe als partner van de Stadsschouwburg Foundation. In het nieuwe contract wordt GenDx founder.
De Stadsschouwburg Foundation is een alliantie van Utrechtse organisaties en bedrijven die de schouwburg in staat stellen jaarlijks een aantal exclusieve (en kostbare) producties in het programma op te nemen. Als waardering voor hun steun biedt de schouwburg deelnemers aan de foundation bijzondere faciliteiten zoals ontvangsten van relaties, ontmoetingen tussen founders en diverse vormen van exposure. Andere Founders zijn Douwe Egberts, Rabobank Utrecht e.o. en de Provincie Utrecht.

Wietse Mulder (PhD, CEO van GenDx):
“Drie jaar geleden zijn we partner geworden van de Stadsschouwburg, met het volgende statement: ‘Wij weten wat het betekent om als donor het verschil te maken. Daarom is GenDx partner van Stadschouwburg Utrecht.’
GenDx is een Utrechtse Life Science onderneming en gevestigd op het Utrecht Science Park. In een tijd waarin nagenoeg geen voorstellingen kunnen worden gegeven bij de Stadsschouwburg, willen wij onze betrokkenheid versterken door founder te worden.
De relatie met de stadsschouwburg ligt ons na aan het hart en wordt door onze medewerkers zeer gewaardeerd. Zij kijken er naar uit om weer een voorstelling van eigen keuze bij te kunnen wonen. Daarnaast zijn we een tevreden bezoeker van restaurant Zindering, waar we regelmatig met onze gasten naar toe gaan.”

Joost Kok (adjunct-directeur Stadsschouwburg Utrecht):
“De Stadsschouwburg Foundation is een fijne plek waar veel Utrechtse bedrijven zich thuis voelen. De founders en partners steunen al jaren de activiteiten van Stadsschouwburg Utrecht. Zeker in deze tijd is deze steun hard nodig. We investeren veel in relatiebeheer waarbij het persoonlijke contact voorop staat. Dat dit werkt zien we aan een trouwe partner als GenDx, die nu besloten heeft om founder te worden. Het is hartverwarmend om te zien dat Gendx zoveel vertrouwen in ons uitspreekt, voor nu en in de toekomst.”


Foto:
V.l.n.r.: Joost Kok (adjunct-directeur Stadsschouwburg Utrecht), Wietse Mulder (PhD, CEO GenDx) en Dennis Dercksen (manager sales & sponsoring Stadsschouwburg Utrecht)

Tulip Challenge aftermovie

The Tulip Challenge was initiated during the COVID lockdown period to encourage people to stay fit, be connected with the HLA family and united by the common goal: to enhance the outcome of transplantation.

 

Last May, 87 participants from 14 different countries have completed the Tulip Challenge. Thank you for sharing your photos and videos of unique, impressive and exhausting workouts, which will definitely inspire all of us for the future.

Together, we have raised €2175 which will be donated to the organizers of the 18th International HLA & Immunogenetics Workshop to support research on COVID-19. Next week, the cheque will be handed over to the chairmen Eric Spierings and Sebastiaan Heidt.

Tulip Challenge Dashboard – Week 4

We have come to the end of the Tulip Challenge in May 2020. Thank you all for joining and sharing your workout with us! We are glad that the Tulip Challenge kept us connected with the HLA family during these extraordinary times and that we are united by the common goal: to enhance the outcome of transplantation.

Thanks to 87 completed Tulip Challenge in 14 different countries, we will donate € 2175 to the organizers of the 18th International HLA & Immunogenetics Workshop to support research on COVID-19.
You can check our photo gallery to see all Tulip Challenge workouts that were done by you: gendx.com/2020/05/tulip-challenge-2020/ 

Tulip Challenge 2020

Tulip Challenge Dashboard – Week 3

With the Tulip Challenge we hope you will be encouraged to stay active and fit to overcome this exceptional period, be connected with the HLA family and united by the common goal: to enhance the outcome of transplantation.

The third week has passed, let’s update you about the Tulip Challenge!
Until now, 44 workouts have been completed with a total distance of 1195.75 KM! Not only running and cycling, but also inline skating and downhill mountain biking, HIIT workouts and jump rope workouts. The workouts have been completed in the Netherlands, the US, the UK (Scotland & England), Italy, Spain, Germany and Belgium.

For those of you who haven’t received their package yet, please be patient. Postal services are delayed worldwide and we trust they are doing their very best to deliver the package asap!

With the weekly Tulip Challenge Dashboard, we will keep you informed about the number of workouts completed. Also have a look at the photos of the completed Tulip Challenges in our photo gallery: gendx.com/2020/05/tulip-challenge-2020/ 

GenDx Distributor Awards 2020

We cooperate closely with our distributors, who also contribute to education and offer services to HLA labs in over 60 countries. During these challenging months, we use the webinar opportunities to keep contact, educate and discuss the ongoing support in the HLA field. Besides discussing our latest product updates, we finished this time with a small ceremony to award 3 distributors who have excelled in the last year in their respective markets, resp. Voden Medical from Italy, Jasika from Croatia and Pensabio from Brazil. Congratulations!

Tulip Challenge Dashboard – Week 2

With the Tulip Challenge we hope you will be encouraged to stay active and fit to overcome this exceptional period, be connected with the HLA family and united by the common goal: to enhance the outcome of transplantation.

We are at the end of the second week of the Tulip Challenge, so it’s time for another update!
Until now, 22 workouts have been completed with a total distance of 481 KM! Not only running and cycling, but also inline skating and downhill mountain biking – how cool is that?

For those of you who haven’t received their package yet, please be patient. Postal services are delayed worldwide and we trust they are doing their very best to deliver the package asap!

With the weekly Tulip Challenge Dashboard, we will keep you informed about the number of workouts completed. Also have a look at the photos of the completed Tulip Challenges in our photo gallery: gendx.com/2020/05/tulip-challenge-2020/ 

Continuation of our business related to the COVID-19 outbreak

Dear customers,

We follow the developing outbreak of COVID-19 closely by monitoring the World Health Organization (WHO) and the Dutch government including the health measures of National Institute for Public Health and the Environment (RIVM) in the Netherlands. In general, we have defined and safeguarded our critical functions where possible and actively minimized physical contacts in our company, e.g. by increasing online cooperation and working in shifts.

The following is important for you to know:

  • Both our Dutch head office and US office are open as usual. You can contact us via our general email address and phone number(s): info@gendx.com and +31 (0)30 252 3799  or +1 (312) 815 5006
  • Our support team remains available for all your questions. Our intention is to answer your questions within 24 hours.
  • We have secured the safety and quality of our products by working in shifts to continue production and logistics.
  • Orders continue to be processed and shipped. Please place your order via order@gendx.com  or your local distributor.
  • All physical contact events in the upcoming month are canceled. We will organize some additional webinars instead, e.g. on April 8th the webinar  Multiplex amplification for fast and easy HLA typing is scheduled – click here for more information and registration

Even during this difficult time, we are happy to assist you and we hope that the potential damage for all our customers may be limited. Please take care of yourself and others, and stay healthy.

Kind regards,

The GenDx Team

Tulip Challenge Dashboard – Week 1

With the Tulip Challenge we hope you will be encouraged to stay active and fit to overcome this exceptional period, be connected with the HLA family and united by the common goal: to enhance the outcome of transplantation.

One week has passed since the start of the Tulip Challenge, and we are very pleased with the high number of registrations from all over the world! The first workouts have been completed in the Netherlands, Spain and United States and we can’t wait to receive more photos and videos of completed challenges.

With the weekly Tulip Challenge Dashboard, we will keep you informed about the number of workouts completed. Also have a look at the photos of the completed Tulip Challenges in our photo gallery: gendx.com/2020/05/tulip-challenge-2020/ 

May webinar series to commemorate our 15th anniversary

To commemorate our 15th anniversary, we are sharing a series of webinars this year! In the coming weeks we will offer multiple webinars, each taking approximately 30 minutes.

Register for one or multiple webinars via the link(s) below.


Webinar 1: Variability in HLA Expression: Impact on Histocompatibility Assay Interpretation and Immunologic Risk Assessment

May 7, 2020, 3:00 p.m. CEST (Amsterdam time) / noon CST (Chicago time)

We are pleased to welcome our guest speaker, Dr. Luis Hidalgo, to this webinar. Dr. Hidalgo is Associate Professor and Histocompatibility Lab Director at the University of Wisconsin School of Medicine and Public Health.

Register (CEST, Amsterdam)
Register (CST, Chicago)


Webinar 2: Daily practice in an HLA lab: dealing with HLA-DR, a complicated genetic region

May 20, 2020, 3:00 p.m. CEST (Amsterdam time) / noon CST (Chicago time)

We are pleased to welcome our guest speaker, Dr. Nicholas Brown, to our webinar. Dr. Brown is the associate director of the histocompatibility testing laboratory, and assistant professor of pathology and laboratory medicine, at the University of Pennsylvania. Dr. Brown is interested in clinical assays for histocompatibility laboratories and has published reports on NGS typing assays, HLA antibody assays, and crossmatching. In this webinar, he will share his knowledge on the complicated HLA-DR immunogenetics.

Register (CEST, Amsterdam)
Register (CST, Chicago)


Webinar 3:  GenDx case studies *

May 27, 2020, noon CEST (Amsterdam time) / noon CST (Chicago time)

  • Live discussion of NGS data
  • Tips and tricks

Register (CEST, Amsterdam)
Register (CST, Chicago)


* You will receive data files in advance. We ask you to analyze the data and think about what you would report to the clinician. Before the webinar we would like to receive your answers and questions on education@gendx.com so we can address them in the live webinar. (software trial license available upon request)  We look forward to receiving your interpretation of the data!
For each webinar you attend, you will receive 0.15 continuing education credits (CECs).

We are looking forward to virtually meeting you during one or multiple webinars! If you have any questions, please contact us directly via education@gendx.com

Join us for the Tulip Challenge

Are you up for a workout challenge?

As an alternative to the well-known Tulip Run, the sports highlight of the EFI meetings, we invite you to join the Tulip Challenge in May 2020. This challenge can be completed from any city, country and continent in the world and goes beyond running since some preventive measures restrict people to go outside.

Share the workout that keeps you healthy and stay connected with the HLA field, as we used to do with the Tulip Run.

Are you in?

5 Steps to participate in the Tulip Challenge

  • Register before May 15 via: tulip-challenge-2020.eventbrite.co.uk and wait for your welcome package to arrive at your home.*
  • Use the textile marker to write down your city or country on the front of the T-shirt. We also include a card to write down your workout.
  • Run, walk, plank, squat or do another (indoor) workout in May, wearing your special edition Tulip Challenge T-shirt and make a photo or video.
  • Send the photo or video to marketing@gendx.com or share via your social media channel using #tulipchallenge2020. We will publish and/or share your workout on our social media channels to inspire others in the HLA field all around the world to do your workout as well.
  • For every submission, GenDx will donate €25,- to the organizers of the 18th International HLA & Immunogenetics Workshop to support research on COVID-19.

*We have a limited amount of Sports T-shirts available. Register soon to receive this special edition Tulip Challenge Sports T-shirt.

With this challenge we hope you will be encouraged to stay active and fit to overcome this exceptional period, be connected with the HLA family and united by the common goal: to enhance the outcome of transplantation.

Introducing the renewed Custom Lab Service

GenDx is proudly introducing the renewed Custom Lab Service. Empowered by our unsurpassed HLA expertise and advanced high-quality systems, we are fully committed to providing HLA typing services to facilitate HLA research.

Are you a CRO, CDMO, Pharma or a research organization and in need for support of your HLA typing project? You can just send us the DNA you would like to analyze and GenDx will report back the tissue typing results. Turnaround time and follow-up depends on the request.

For more information on our Custom Lab  Service, click here or contact us.

 

EFI postponed until 2021

Covid-19 update: Statement from EFI & BSHI Committees

Due to the COVID-19 pandemic, EFI 2020 has been postponed and will now take place on 

Thursday 22nd April – Sunday 25th April 2021

The postponed conference shall take place at the same venue, SEC Glasgow. Email communications have been sent to all stakeholders.  In order to minimise inconvenience and in anticipation of your questions we have provided some Frequently Asked Questions (FAQs) to assist you.

We look forward to seeing you in Glasgow in April 2021!

Webinar series to commemorate our 15th anniversary

To commemorate our 15th anniversary, we are sharing a series of webinars this year! We believe that continuous education is important for all HLA typers and therefore we have developed the Teaching Session Web Series. In the coming weeks we will offer multiple webinars, each taking approximately 45 minutes.

In the first two webinars we will discuss the principles of the NGS workflow and demonstrate data analysis in NGSengine. In the third and fourth webinar we will deal with challenging case studies for in-depth data analysis and interactive discussions.

Webinar 1: April 14, Basics of the NGS workflow
Webinar 2: April 16, Introduction to NGSengine®
Webinar 3: April 21, GenDx case studies (easy/medium level)
Webinar 4: April 23, GenDx case studies (advanced level)

Do you want to learn more about the NGS workflow, NGSengine, or strengthen your data analysis skills? Register for one or multiple webinars of our Teaching Session Web Series via the link(s) below.


Webinar 1: April 14, 2020, 12:00 PM

Basics of NGS workflow

  • Introduction to high-resolution HLA typing with NGS
  • NGS workflows for HLA typing

Register (CEST, Amsterdam)
Register (CDT, Chicago)


Webinar 2: April 16, 2020, 12:00 PM

Introduction to NGSengine

  • NGSengine software demo
  • Tips and tricks for effective data analysis
  • Demonstration of a GenDx case study

Register (CEST, Amsterdam)
Register (CDT, Chicago)


Webinar 3: April 21, 2020, 12:00 PM

GenDx case studies (easy/medium level)*

  • Live discussion of NGS data
  • Tips and tricks

Register (CEST, Amsterdam)
Register (CDT, Chicago)


Webinar 4: April 23, 2020, 12:00 PM

GenDx case studies (advanced level)*

  • Live discussion of NGS data
  • Tips and tricks

Register (CEST, Amsterdam)
Register (CDT, Chicago)

* You will receive data files in advance. We ask you to analyze the data and think about what you would report to the clinician. Before the webinar we would like to receive your answers and questions on education@gendx.com so we can address them in the live webinar. (software trial license available upon request)  We look forward to receiving your interpretation of the data!
For each webinar you attend, you will receive 0.15 continuing education credits (CECs).

We are looking forward to virtually meeting you during one or multiple webinars! If you have any questions, please contact us directly via education@gendx.com

Webinar 8 April: Multiplex amplification for fast and easy HLA typing

At GenDx we strive for fast and easy sequencing-based HLA typing. Using a multiplexed PCR strategy significantly reduces pipetting steps and hands-on time.

In this webinar, Sake van Wageningen PhD, Project Manager R&D, will present the GenDx multiplexed strategies and give a development update on our latest 11-loci multiplex product. He will also demonstrate how multiplexed data is analyzed in NGSengine.

NEW! Attend the webinar and receive 0.15 continuing education credits (CECs).

More info and registration

 

Meet us at the EWIC 2020

Are you attending the upcoming East West Immunogenetics Conference in Budapest? Join our presentation on Friday, March 6, or meet us at our booth.

“Solving Biological Mysteries with NGS: Three Alleles in One Sample”

by Sebastian Ziemann PhD

Clinical samples that are sent for HLA typing can sometimes contain surprising peculiarities, such as three alleles present in one sample. A situation like this can lead to inexplicable heterozygous or questionable positions that cannot be easily interpreted. Upon receiving a sample like this, we did further investigation to find out what was going on in the sample.

We are looking forward to meeting you in Budapest!

15 years GenDx: ‘Excellence in sharing’

A new decade has started. And, 2020 is a remarkable year as GenDx celebrates its 15th anniversary! ‘Excellence in sharing’ is our theme for 2020. One of the values of GenDx which will get a lot of attention by offering you interesting topics and in depth information related to the HLA field. Keep an eye on our event calendar for webinars and educational events. Visit us during the main congresses or just contact our team to learn more about our continuously expanding product portfolio. We are happy to share our successes with you!

NGSgo®-AmpX v2 and NGSgo®-MX6-1 now registered as CE-marked IVD

We are happy to announce that GenDx has registered NGSgo®-AmpX v2 and NGSgo®-MX6-1 as CE-marked IVD.

The NGSgo®-AmpX v2 and NGSgo®-MX6-1 primer kits are intended for the amplification of both HLA alleles present in a sample for downstream sequencing applications. They are intended for in vitro diagnostic use by professional users in diagnostic laboratories, such as laboratory technicians and physicians, trained in HLA-typing and DNA sequencing.

Customers that are interested in implementing these products to their workflow and wonder whether they could benefit from this registration, can receive more information by contacting their local GenDx distributor or by contacting GenDx directly.

GenDx partners with PIRCHE

Genome Diagnostics B.V. (“GenDx”) announced today that they have entered a collaboration with the Berlin-based company PIRCHE AG and have released a new version of their software NGSengine®. NGSengine, globally considered to be the ultimate Human Leukocyte Antigen (HLA) typing software for multiple NGS platforms, can now export HLA typing results of an individual sample directly to the PIRCHE matching services website. This will facilitate laboratories to predict indirectly recognizable HLA epitopes for either hematopoietic stem cells or solid organs.

About the PIRCHE algorithm
HLA mismatches between donors and recipients may lead to alloreactivity after transplantation. With the identification of numerous new HLA alleles, the risk of alloreactive responses towards HLA mismatches after transplantation has become more challenging to predict. The PIRCHE (Predicted Indirectly ReCognizable HLA Epitopes) algorithm has been developed to estimate the risk associated to alloreactive T-cell responses. The PIRCHE algorithm addresses the indirect recognition of HLA mismatches. It aims to improve transplant outcome by reducing Graft-versus-Host Disease and by enhancing Graf-versus-Leukemia effects after hematopoietic stem cell transplantation and cord blood transplantation. In the field of organ transplantation, the algorithm allows estimating the incidence of developing donor-specific antibodies against the transplant, which is considered the major risk of graft failure.

About High-Resolution HLA Typing
The HLA system consists of a large family of highly variable genes and allelic variants which form the basis of the human immunological defense system. In stem cell transplantation, matching patient and donor is vital as small differences between HLA alleles may have serious effects on the outcome of transplantation. High-resolution typing is a technology which enables determination of variations in nucleotides, making it ideal for stem cell transplantation purposes.
GenDx offers the NGSgo® reagent line and the NGSengine software package for NGS-based HLA typing.

GenDx sponsors KIR Polymorphism Workshop 2020

GenDx is proud to be sponsor of the KIR polymorphism Workshop 2020 which will be held May 14-17 at the historic Stanley Hotel in Estes Park, Colorado, USA.

The workshop will focus on the current research in the field specifically related to killer cell immunoglobulin-like receptors and their polymorphism. There will be sessions covering population genetics, evolution, basic immunology, implications for cancer and its treatment, including transplantation, and in immune-mediated diseases and reproduction.

Interested?

Registration is now open: https://lnkd.in/dZRRz2v

To submit your abstract: https://lnkd.in/dvkReQ6